[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"updates-archive-2026-05-07-1":3},{"date":4,"filings":5,"has_more":565,"limit":566,"page":567,"total_count":568},"2026-05-07",[6,14,22,27,32,37,42,47,53,58,65,70,75,80,85,90,95,100,105,110,115,120,127,133,140,145,152,159,164,171,178,183,188,193,200,206,211,217,222,227,234,239,244,249,255,260,265,270,277,282,287,292,297,303,310,317,322,329,334,339,345,352,357,363,368,373,378,385,390,395,400,405,410,415,420,425,430,437,443,448,455,460,465,470,475,481,486,491,496,501,506,513,519,526,531,536,542,547,553,560],{"company_name":7,"filing_date":8,"filing_source":9,"headline":10,"id":11,"stock_code":12,"summary_text":13},"Vikram Solar Limited","2026-05-07T23:51:39.138000","NSE","New CEO Appointed and Key Management Changes Announced","69fcd85babd16353d2ffb229","544488","*   Mr. Sameer Nagpal has been appointed as the new CEO and Executive Director.\n*   **Red Flag:** A significant discrepancy was noted in the filing. The new CEO's age is listed as 36, while his experience is stated as \"over three decades.\"\n*   Ms. Neha Agrawal has been elevated to Whole-time Director and Key Managerial Personnel (KMP).\n*   Mr. Gyanesh Chaudhary, who is related to the promoter, has been re-appointed as Managing Director.",{"company_name":15,"filing_date":16,"filing_source":17,"headline":18,"id":19,"stock_code":20,"summary_text":21},"Biocon Ltd","2026-05-07T23:46:41.172000","BSE","Biocon's FY26 Profit Plummets; Board Approves Full Takeover of Biocon Biologics","69fcd7675236ec998939fb57","BIOCON","*   Consolidated revenue grew 10.6% in FY26, but net profit plummeted to ₹3,688 Million from ₹14,294 Million in FY25, hit by a steep decline in segment profitability and exceptional costs of ₹4,029 Million.\n*   The Generics segment swung to a loss, and the core Biosimilars segment's profit halved despite strong revenue growth, indicating severe margin pressure.\n*   The Board approved a plan to fully acquire its subsidiary, Biocon Biologics Ltd (BBL), by increasing its stake to ~99.99% through a share swap, aiming to simplify the corporate structure.\n*   A final dividend of ₹0.50 per share (10%) has been recommended for the financial year 2026.\n*   The Board has proposed appointing M\u002Fs. S. R. Batliboi & Associates LLP as new statutory auditors and is seeking a major expansion of the Board with several new director appointments.",{"company_name":15,"filing_date":23,"filing_source":17,"headline":24,"id":25,"stock_code":20,"summary_text":26},"2026-05-07T23:46:41.142000","FY26 Profit Halves, Moves to Fully Integrate Biocon Biologics","69fcd76ca157653c663a13a1","*   FY26 consolidated profit (PAT) fell sharply to ₹3,688 million from ₹14,294 million in FY25, impacted by exceptional items (₹4,029M) and lower profitability.\n*   The Generics segment swung to a loss of ₹1,348 million from a profit of ₹1,755 million last year, marking it a key area of concern.\n*   The Board approved a major restructuring to make Biocon Biologics Limited (BBL) a ~99.99% subsidiary via a preferential share swap.\n*   A final dividend of ₹0.50 per share (10%) has been recommended for the financial year ended March 31, 2026.\n*   The Board proposed the appointment of M\u002Fs. S. R. Batliboi & Associates LLP as the new statutory auditors, replacing the retiring M\u002Fs. B S R & Co. LLP.",{"company_name":15,"filing_date":28,"filing_source":17,"headline":29,"id":30,"stock_code":20,"summary_text":31},"2026-05-07T23:46:41.132000","Reports Mixed FY26 Results, Announces Major Restructuring & Board Shake-up","69fcd759ec7f5de862c57726","*   \u003Cb>FY26 Performance:\u003C\u002Fb> Revenue grew 10.6%, but PBT fell ~53%. The Generics segment reported a loss of ₹1,348M, and Biosimilars' PBT halved despite strong revenue growth.\n*   \u003Cb>Major Restructuring:\u003C\u002Fb> The Board approved the full integration of its subsidiary, Biocon Biologics (BBL), making it a wholly-owned subsidiary via a share swap valued at ₹330.73 Crores.\n*   \u003Cb>Significant Board Overhaul:\u003C\u002Fb> Proposes the appointment of six new directors, including five new Independent Directors, to create a \"Unified Global Biopharmaceutical Leader\".\n*   \u003Cb>Dividend & Auditor Change:\u003C\u002Fb> Recommended a final dividend of ₹0.50 per share and proposed the appointment of M\u002Fs. S. R. Batliboi & Associates LLP as new statutory auditors.\n*   \u003Cb>Governance Red Flag:\u003C\u002Fb> The appointment of a new director, Mr. Thomas Jason Roberts, is noted as a related-party transaction as he is a relative of individuals associated with the promoter group.",{"company_name":15,"filing_date":33,"filing_source":17,"headline":34,"id":35,"stock_code":20,"summary_text":36},"2026-05-07T23:41:41.278000","Biocon to Fully Integrate Biosimilars Arm; Generics Segment Slips to a Loss","69fcd63d5236ec998939fb52","• \u003Cb>Mixed FY26 Results:\u003C\u002Fb> While Biosimilars drove 15.7% revenue growth, the Generics segment swung to a significant loss of ₹1,348 Million, dragging down overall group profitability.\n• \u003Cb>Major Restructuring:\u003C\u002Fb> The company will fully integrate its subsidiary Biocon Biologics (BBL) by acquiring the remaining stake via a share swap, aiming to create a unified global biopharma leader.\n• \u003Cb>Dividend Declared:\u003C\u002Fb> The Board has recommended a final dividend of ₹0.50 per equity share for FY26, subject to shareholder approval.\n• \u003Cb>Change in Auditors:\u003C\u002Fb> A proposal to appoint M\u002Fs. S. R. Batliboi & Associates LLP as the new Statutory Auditors, replacing the retiring M\u002Fs. B S R & Co. LLP.\n• \u003Cb>Board Expansion:\u003C\u002Fb> The Board will be expanded with the appointment of five new Independent Directors and one Non-Executive Director as part of the strategic realignment.",{"company_name":15,"filing_date":38,"filing_source":17,"headline":39,"id":40,"stock_code":20,"summary_text":41},"2026-05-07T23:41:41.274000","Posts Mixed FY26 Results, Announces Full BBL Integration & Major Board Overhaul","69fcd62bf35e30561cff9738","\u003Cul>\n\u003Cli>\u003Cb>FY26 Financials:\u003C\u002Fb> Consolidated Revenue grew 10.6% to ₹1,73,380M, but Profit Before Tax fell 53% to ₹9,403M, impacted by exceptional items.\u003C\u002Fli>\n\u003Cli>\u003Cb>Segment Performance:\u003C\u002Fb> The Generics segment swung to a loss of ₹1,348M, a major red flag. Biosimilars revenue grew 15.7%, driving overall top-line growth.\u003C\u002Fli>\n\u003Cli>\u003Cb>Major Restructuring:\u003C\u002Fb> The Board approved making Biocon Biologics Ltd (BBL) a wholly-owned subsidiary through a share swap, aiming to create a unified global entity.\u003C\u002Fli>\n\u003Cli>\u003Cb>Governance Shake-up:\u003C\u002Fb> A significant board overhaul is planned with the appointment of six new directors. The company also recommended changing its Statutory Auditors.\u003C\u002Fli>\n\u003Cli>\u003Cb>Dividend:\u003C\u002Fb> A final dividend of ₹0.50 per equity share (10%) has been recommended for FY26.\u003C\u002Fli>\n\u003C\u002Ful>",{"company_name":15,"filing_date":43,"filing_source":17,"headline":44,"id":45,"stock_code":20,"summary_text":46},"2026-05-07T23:41:41.148000","FY26 Results, Dividend & Major Restructuring Announced","69fcd639bf8f716f13ffa7b6","*   **Financials:** Consolidated revenue for FY26 grew 10.6% YoY, but profitability was impacted. The Generics segment reported a significant loss of ₹1,348 million, a sharp reversal from a profit last year.\n*   **Dividend:** The Board recommended a final dividend of ₹0.50 per share (10%) for the financial year ended 31 March 2026.\n*   **Major Restructuring:** The company is moving to fully integrate its subsidiary, Biocon Biologics Limited (BBL), by acquiring the remaining stake for up to ₹330.73 Crores through a preferential share issue.\n*   **Governance Change:** The Board has recommended appointing S. R. Batliboi & Associates LLP as the new statutory auditors, replacing the retiring auditors, B S R & Co. LLP.\n*   **Red Flag:** Results include significant exceptional costs of ₹4,029 million related to the BBL integration, restructuring, and inventory provisions, which obscure underlying profitability.",{"company_name":48,"filing_date":49,"filing_source":9,"headline":50,"id":51,"stock_code":20,"summary_text":52},"Biocon Limited","2026-05-07T23:41:39.387000","Announces Major Restructuring, Board Overhaul, and Auditor Change","69fcd6250c6b4fb98a923055","*   \u003Cb>Major Restructuring:\u003C\u002Fb> The Board has approved the full integration of its subsidiary, Biocon Biologics Limited (BBL), making it a wholly-owned subsidiary through a share swap valued at ₹330.73 Crores.\n*   \u003Cb>Auditor Change:\u003C\u002Fb> Proposed a change in Statutory Auditors from B S R & Co. LLP to S. R. Batliboi & Associates LLP, a significant governance event.\n*   \u003Cb>Board Overhaul:\u003C\u002Fb> Announced a major board refresh with the appointment of six new directors, including five Independent Directors, to guide the newly integrated entity.\n*   \u003Cb>Financial Performance:\u003C\u002Fb> Reported 10.6% YoY growth in consolidated revenue for FY26, driven by the Biosimilars segment. However, the Generics segment reported a loss of ₹1,348 Million.\n*   \u003Cb>Dividend:\u003C\u002Fb> Recommended a final dividend of ₹0.50 per equity share for the financial year ended March 31, 2026.",{"company_name":48,"filing_date":54,"filing_source":9,"headline":55,"id":56,"stock_code":20,"summary_text":57},"2026-05-07T23:41:39.372000","FY26 Results: Integration Complete, New Leadership Takes Helm","69fcd634890e096a6fc59235","*   Reported 13% YoY growth in adjusted operating revenue for FY26, driven by the Biosimilars segment which grew 16%.\n*   Successfully completed the major integration of its biosimilars and generics businesses to form a unified enterprise.\n*   Announced significant leadership changes, appointing Shreehas Tambe as the new CEO & MD.\n*   Key Concern: The Generics segment showed strong revenue growth but posted a very low 8% EBITDA margin in Q4, indicating profitability challenges.\n*   Strengthened the balance sheet by reducing total debt by ~₹2,931 Crore and recommended a final dividend of Re. 0.50 per share.",{"company_name":59,"filing_date":60,"filing_source":9,"headline":61,"id":62,"stock_code":63,"summary_text":64},"Oberoi Realty Limited","2026-05-07T23:41:39.352000","Acquires Prime Juhu Property for Retail & Hospitality Development","69fcd609abd16353d2ffb219","OBEROIRLTY","• As part of a consortium, Oberoi Realty has acquired Hotel Horizon Private Limited (HHPL) through an insolvency resolution process.\n• The company invested ₹460 Crore for a 49.999% shareholding in HHPL.\n• The key asset acquired is a prime 7,500 sq. mtr. sea-facing land parcel in Juhu, Mumbai.\n• The site is earmarked for a future \"Retail cum Hospitality\" project, aligning with the company's core business.",{"company_name":15,"filing_date":66,"filing_source":17,"headline":67,"id":68,"stock_code":20,"summary_text":69},"2026-05-07T23:37:20.671000","FY26 Results: Profitability Plummets Amid Major Corporate Overhaul","69fcd52df43b112c8d9215c2","• \u003Cb>Profitability Crisis:\u003C\u002Fb> For FY26, the Generics segment reported a loss of ₹1,348 Million (vs. a profit last year), and the Biosimilars segment's profit before tax (PBT) fell by over 50%, despite revenue growth.\n• \u003Cb>Major Restructuring & Dilution:\u003C\u002Fb> The company will fully integrate its subsidiary, Biocon Biologics (BBL), through a share swap. This will lead to equity dilution for existing shareholders.\n• \u003Cb>Auditor Change:\u003C\u002Fb> The Board has recommended replacing statutory auditors M\u002Fs. B S R & Co. LLP with M\u002Fs. S. R. Batliboi & Associates LLP, a significant governance event.\n• \u003Cb>Board Overhaul:\u003C\u002Fb> A major board restructuring is underway with the proposed appointment of six new directors.\n• \u003Cb>Dividend:\u003C\u002Fb> A final dividend of ₹0.50 per share has been recommended for the financial year 2025-26.",{"company_name":15,"filing_date":71,"filing_source":17,"headline":72,"id":73,"stock_code":20,"summary_text":74},"2026-05-07T23:37:20.661000","FY26 Profit Drops 74% Amid Major Restructuring to Fully Acquire Biocon Biologics","69fcd535abd16353d2ffb215","• \u003Cb>Profit Plummets:\u003C\u002Fb> Consolidated Net Profit for FY26 fell 74% to ₹3,688 Million, driven by high exceptional costs related to restructuring and declining segment profitability. Basic EPS dropped to ₹2.88 from ₹8.46.\n• \u003Cb>Major Restructuring:\u003C\u002Fb> The Board approved a plan to acquire the remaining stake in its key subsidiary, Biocon Biologics Ltd. (BBL), to make it a wholly-owned subsidiary through a share swap.\n• \u003Cb>Generics Segment in Loss:\u003C\u002Fb> The Generics business swung to a significant loss of ₹1,348 Million, a major deterioration from last year's profit of ₹1,755 Million.\n• \u003Cb>Dividend Declared:\u003C\u002Fb> A final dividend of Re. 0.50 per share (10%) has been recommended for the financial year.\n• \u003Cb>Governance Overhaul:\u003C\u002Fb> The company announced a change in Statutory Auditors and a significant board reconstitution, including the appointment of five new Independent Directors.",{"company_name":15,"filing_date":76,"filing_source":17,"headline":77,"id":78,"stock_code":20,"summary_text":79},"2026-05-07T23:37:20.626000","FY26 Results: Revenue Grows 11%, But Net Profit Plummets 62% on Major Restructuring Costs","69fcd535c9cbead9b3c586de","*   \u003Cb>Drastic Profit Decline:\u003C\u002Fb> Consolidated Net Profit attributable to shareholders for FY2026 fell 61.9% to ₹3,856 Million, driven by over ₹4,000 Million in net exceptional losses related to restructuring.\n*   \u003Cb>Loss-Making Segment:\u003C\u002Fb> The core Generics business turned unprofitable, reporting a pre-tax loss of ₹1,348 Million for the year, a significant downturn from a profit in the previous year.\n*   \u003Cb>Major Restructuring:\u003C\u002Fb> The Board approved a plan to consolidate its material subsidiary, Biocon Biologics Limited (BBL), to ~99.99% ownership to simplify the corporate structure.\n*   \u003Cb>Dividend Recommended:\u003C\u002Fb> A final dividend of ₹0.50 per equity share (10%) has been recommended for the financial year ended March 31, 2026.\n*   \u003Cb>Board Overhaul:\u003C\u002Fb> A significant board reconstitution was approved, including the appointment of six new directors and a new statutory auditor, M\u002Fs. S. R. Batliboi & Associates LLP.",{"company_name":48,"filing_date":81,"filing_source":9,"headline":82,"id":83,"stock_code":20,"summary_text":84},"2026-05-07T23:36:39.567000","Biocon to Fully Integrate Biologics Arm Amid Profit Slump & Board Overhaul","69fcd500890e096a6fc5922d","*   \u003Cb>Major Restructuring:\u003C\u002Fb> The company will fully integrate its subsidiary, Biocon Biologics Limited (BBL), making it a wholly-owned subsidiary via a preferential share issue.\n*   \u003Cb>Severe Profit Decline:\u003C\u002Fb> FY26 results show a sharp drop in profitability. The Generics segment reported a loss of ₹(1,348) million, and the high-growth Biosimilars segment's profit fell by over 50%.\n*   \u003Cb>Board Overhaul:\u003C\u002Fb> A significant governance change is underway with the appointment of six new directors to create a \"Unified Global Biopharmaceutical Leader\" post-integration.\n*   \u003Cb>Dividend Recommended:\u003C\u002Fb> The Board has recommended a final dividend of 10% (Re. 0.50 per share) for the financial year ended March 31, 2026.\n*   \u003Cb>Exceptional Costs:\u003C\u002Fb> Financials were heavily impacted by large, non-recurring exceptional items totaling a net charge of ₹4,029 million, related to integration costs, severance, and litigation.",{"company_name":48,"filing_date":86,"filing_source":9,"headline":87,"id":88,"stock_code":20,"summary_text":89},"2026-05-07T23:36:39.418000","Biocon Unveils Major Overhaul: Full BBL Takeover & New Board","69fcd506ecaa861d94922530","*   \u003Cb>Major Restructuring:\u003C\u002Fb> Approved the \u003Cb>full integration of its subsidiary, Biocon Biologics Limited (BBL)\u003C\u002Fb>, via a share swap to simplify the corporate structure.\n*   \u003Cb>Board & Auditor Overhaul:\u003C\u002Fb> Announced a significant \u003Cb>board restructuring\u003C\u002Fb> with six new director appointments and a change in statutory auditors to M\u002Fs. S. R. Batliboi & Associates LLP.\n*   \u003Cb>FY26 Financials:\u003C\u002Fb> Reported \u003Cb>10.6% YoY growth\u003C\u002Fb> in consolidated revenue, but the \u003Cb>Generics segment swung to a significant loss\u003C\u002Fb> of ₹1,348 Million.\n*   \u003Cb>Dividend Declared:\u003C\u002Fb> Recommended a final dividend of \u003Cb>₹0.50 per share\u003C\u002Fb> for the financial year ended March 31, 2026.",{"company_name":48,"filing_date":91,"filing_source":9,"headline":92,"id":93,"stock_code":20,"summary_text":94},"2026-05-07T23:36:39.378000","FY26 Results: Profit Plummets, Board Approves Full BBL Integration & Dividend","69fcd50da157653c663a138e","• Consolidated Profit for the year fell sharply to ₹3,688 million from ₹14,294 million last year, with Basic EPS collapsing from ₹8.46 to ₹2.88.\n• The Board recommended a final dividend of ₹0.50 per share (10%) for the financial year 2025-26.\n• A major restructuring was approved to make Biocon Biologics Limited (BBL) a wholly-owned subsidiary via a share swap, aiming to simplify the corporate structure.\n• Results were heavily impacted by exceptional losses of ₹4,029 million related to the BBL integration, restructuring costs, and inventory provisions.\n• Segment performance was poor: the Generics business swung to a loss, and the Biosimilars segment's profit fell by 50.9% despite strong revenue growth.\n• The Board proposed a change in statutory auditors and announced a significant refresh of the Board of Directors with multiple new appointments.",{"company_name":48,"filing_date":96,"filing_source":9,"headline":97,"id":98,"stock_code":20,"summary_text":99},"2026-05-07T23:36:39.359000","FY26 Results: Profits Plunge 74% on BBL Integration Costs, Major Restructuring Announced","69fcd50e0c6b4fb98a92304e","*   Consolidated Net Profit for FY26 plummeted by 74.2% to ₹3,688 Million, despite a 10.9% rise in revenue.\n*   The Generics business reported a loss of ₹1,348 Million (vs. a profit last year), and the Biosimilars segment's profit halved despite strong revenue growth.\n*   Profitability was severely hit by ₹4,029 Million in exceptional costs, primarily for the integration of Biocon Biologics (BBL).\n*   The Board approved a major restructuring to make BBL a ~99.99% subsidiary, involving a share swap to acquire the remaining stake.\n*   A final dividend of Re. 0.50 per share (10%) has been recommended for FY26.\n*   The company announced a major board overhaul and proposed a change in statutory auditors from B S R & Co. LLP to S. R. Batliboi & Associates LLP.",{"company_name":15,"filing_date":101,"filing_source":17,"headline":102,"id":103,"stock_code":20,"summary_text":104},"2026-05-07T23:32:00.997000","Posts Sharp Profit Drop, Announces Major Restructuring & Final Dividend","69fcd3ecabd16353d2ffb20e","*   **Profit Plummets:** Consolidated Profit After Tax for FY26 fell 74% to ₹3,688 Million from ₹14,294 Million in FY25. The Generics segment is now loss-making.\n*   **Major Restructuring:** The Board approved a plan to fully integrate its subsidiary, Biocon Biologics (BBL), making it a wholly-owned entity via a share swap. This led to significant one-time exceptional costs of ₹4,029 Million.\n*   **Dividend Declared:** A final dividend of Re. 0.50 per equity share has been recommended for the financial year ended March 31, 2026, subject to shareholder approval.\n*   **Governance Overhaul:** Proposing the appointment of S. R. Batliboi & Associates LLP as new statutory auditors and a major Board expansion with six new directors.",{"company_name":15,"filing_date":106,"filing_source":17,"headline":107,"id":108,"stock_code":20,"summary_text":109},"2026-05-07T23:32:00.963000","FY26 Results: Unified Strategy Drives 13% Revenue Growth, New Leadership Takes Helm","69fcd3d6890e096a6fc59224","*   Consolidated revenue from operations grew 13% YoY to ₹16,927 Cr for FY26.\n*   Strong segment performance with Biosimilars revenue up 16% and adjusted Generics revenue up 17% YoY.\n*   The Biosimilars segment's adjusted EBITDA surged 40% YoY, driving profitability.\n*   Completed integration into a single 'unified biopharma entity' and appointed Shreehas Tambe as new CEO & MD, along with several new board members.\n*   Launched key Denosumab biosimilars in the U.S. and secured FDA approval for generic Liraglutide.\n*   The Board recommended a final dividend of Re. 0.50 per share.",{"company_name":48,"filing_date":111,"filing_source":9,"headline":112,"id":113,"stock_code":20,"summary_text":114},"2026-05-07T23:31:39.530000","Strategic Overhaul Hits FY26 Profits Hard","69fcd3de0c6b4fb98a923049","*   **Financials:** Consolidated Profit After Tax (PAT) plunged 74% to ₹3.7 Billion in FY26, despite an 11% revenue increase. The drop is due to over ₹4 Billion in one-time costs related to restructuring.\n*   **Restructuring:** Biocon is fully integrating its subsidiary, Biocon Biologics (BBL), via a share swap to make it a wholly-owned entity, aiming to create a \"Unified Global Biopharmaceutical Leader.\"\n*   **Segment Performance:** The Generics business swung to a significant loss of ₹1.3 Billion. The Biosimilars segment, while growing revenue, saw its profit halve.\n*   **Governance Changes:** The company is changing its statutory auditors (from B S R & Co. LLP to S. R. Batliboi & Associates LLP) and significantly expanding its Board of Directors.\n*   **Shareholder Impact:** A final dividend of ₹0.50 per share has been recommended. Shareholders face a sharp drop in profitability and minor equity dilution from the restructuring.",{"company_name":15,"filing_date":116,"filing_source":17,"headline":117,"id":118,"stock_code":20,"summary_text":119},"2026-05-07T23:26:40.928000","FY26 Results: Revenue Up, Profits Plunge Amid Major BBL Restructuring","69fcd2a2ecaa861d94922524","*   \u003Cb>Mixed Financials:\u003C\u002Fb> Consolidated revenue grew 10.9% YoY to ₹1,69,270 Million, but total segment Profit Before Tax (PBT) plummeted by 53%. The company reported large exceptional charges of ₹4,029 Million.\n*   \u003Cb>Segment Performance:\u003C\u002Fb> The Generics business swung to a loss of ₹(1,348) Million. The high-growth Biosimilars business saw its PBT fall by over 50% despite a 15.7% rise in revenue.\n*   \u003Cb>Major Restructuring:\u003C\u002Fb> The company will make Biocon Biologics Limited (BBL) a wholly-owned subsidiary via a share swap. This will result in the issuance of new shares, causing dilution for existing shareholders.\n*   \u003Cb>Dividend Declared:\u003C\u002Fb> The Board has recommended a final dividend of ₹0.50 per equity share for the financial year 2025-26.\n*   \u003Cb>Governance Overhaul:\u003C\u002Fb> A new statutory auditor (M\u002Fs. S. R. Batliboi & Associates LLP) has been recommended, and a large slate of new, high-profile directors will be appointed to guide the company's integration strategy.",{"company_name":121,"filing_date":122,"filing_source":9,"headline":123,"id":124,"stock_code":125,"summary_text":126},"Britannia Industries Limited","2026-05-07T23:26:39.423000","Board Recommends Final Dividend of ₹90.5 Per Share","69fcd2780c6b4fb98a923043","BRITANNIA","*   The Board of Directors has recommended a final dividend of **₹90.5 per equity share** for the financial year 2025-26.\n*   This dividend is subject to shareholder approval at the upcoming Annual General Meeting (AGM).\n*   The **Record Date** to be eligible for the dividend is **07 August 2026**.\n*   The dividend payment is scheduled to be completed between 07 August 2026 and 05 September 2026.",{"company_name":128,"filing_date":129,"filing_source":17,"headline":130,"id":131,"stock_code":12,"summary_text":132},"Vikram Solar Ltd","2026-05-07T23:21:40.795000","IPO Project Timelines Delayed, Key Red Flags Noted","69fcd16ebf8f716f13ffa788","\u003Cul>\n\u003Cli>\u003Cb>Project Delay:\u003C\u002Fb> The company reported a 3-month delay for its key Phase I & II capacity expansion projects, pushing completion to mid\u002Flate 2026.\u003C\u002Fli>\n\u003Cli>\u003Cb>Fund Utilization:\u003C\u002Fb> Of the ₹15,000 Mn IPO proceeds, ₹9,691 Mn (~65%) remains unutilized and is temporarily invested in bank deposits.\u003C\u002Fli>\n\u003Cli>\u003Cb>Red Flag - Related Party Transaction:\u003C\u002Fb> A significant transaction of ₹453.60 Mn was noted, where IPO funds were used by a subsidiary to pay the parent company (Vikram Solar) for \"consultancy services\".\u003C\u002Fli>\n\u003Cli>\u003Cb>Execution Risk:\u003C\u002Fb> The monitoring agency noted that project-related government\u002Fstatutory approvals are only \"Partly Obtained\", adding to potential future delays.\u003C\u002Fli>\n\u003C\u002Ful>",{"company_name":134,"filing_date":135,"filing_source":17,"headline":136,"id":137,"stock_code":138,"summary_text":139},"Nilachal Carbo Metalicks Ltd","2026-05-07T23:21:40.770000","Board Meeting to Appoint New CFO and Independent Director","69fcd14f58d87443453a092c","544510","• A Board of Directors meeting is scheduled for Saturday, 09 May 2026.\n• The main agenda is to consider and approve the appointment of a new Chief Financial Officer (CFO) and an Independent Director.\n• These proposed appointments are significant governance events aimed at strengthening the company's management and corporate governance framework.",{"company_name":7,"filing_date":141,"filing_source":9,"headline":142,"id":143,"stock_code":12,"summary_text":144},"2026-05-07T23:21:39.661000","Project Delays and Related Party Transaction Flagged in IPO Fund Report","69fcd16ca157653c663a1375","*   \u003Cb>Project Delays:\u003C\u002Fb> The company reported a 3-month delay for its key Phase-I and Phase-II capacity expansion projects against the original IPO timeline.\n*   \u003Cb>Related Party Transaction:\u003C\u002Fb> A subsidiary used ₹453.60 Million of IPO proceeds to pay the parent company, Vikram Solar, for \"consultancy services,\" a transaction flagged for scrutiny.\n*   \u003Cb>Fund Utilization:\u003C\u002Fb> As of March 31, 2026, approximately 65% of the fresh IPO proceeds (₹9,690.82 Million) remain unutilized and are temporarily invested.\n*   \u003Cb>Report Context:\u003C\u002Fb> This update is from the Monitoring Agency's quarterly report on the utilization of IPO proceeds for the period ending March 31, 2026.",{"company_name":146,"filing_date":147,"filing_source":17,"headline":148,"id":149,"stock_code":150,"summary_text":151},"Shukra Pharmaceuticals Ltd","2026-05-07T23:16:41.118000","FY26 Results Show Strong Growth, but Q4 Loss Raises Concerns","69fcd05fa157653c663a1370","524632","*   Reports strong FY26 performance with consolidated revenue up 66.6% YoY to ₹6,129.10 Lakhs and Profit Before Interest & Tax (PBIT) up 114.5% YoY to ₹2,986.59 Lakhs.\n*   Posts a standalone net loss of ₹172.67 Lakhs in Q4 FY26, a sharp reversal from a net profit of ₹2,036.46 Lakhs in Q3 FY26, indicating high earnings volatility.\n*   Board recommends a final dividend of ₹0.01\u002Fshare and allots 17.35 lakh shares to promoters upon warrant conversion, raising ₹4.42 Crores.\n*   Significant reporting anomaly noted: The new 'Medtech' segment shows zero revenue for FY26 despite having assets of ₹1,268.49 Lakhs allocated to it.",{"company_name":153,"filing_date":154,"filing_source":17,"headline":155,"id":156,"stock_code":157,"summary_text":158},"Vivanza Biosciences Ltd","2026-05-07T23:16:40.467000","Claims Exemption from Related Party Transaction Disclosure","69fcd0325236ec998939fb37","530057","*   The company will NOT be filing the disclosure of Related Party Transactions (RPTs) for the half-year ended March 31, 2026.\n*   This is due to an exemption under SEBI regulations for companies with a paid-up capital below ₹10 Crore and a net worth below ₹25 Crore.\n*   As of March 31, 2025, the company's paid-up capital is ₹4 Crore and its net worth is ₹4.02 Crore, thus meeting the exemption criteria.\n*   \u003Cb>Investor Impact:\u003C\u002Fb> Shareholders will not have access to RPT details for this period, which reduces transparency into the company's dealings with its promoters and management.",{"company_name":153,"filing_date":160,"filing_source":17,"headline":161,"id":162,"stock_code":157,"summary_text":163},"2026-05-07T23:11:40.668000","Reports FY26 Profit, But Q4 Loss & Key Resignation Raise Concerns","69fccf17f43b112c8d9215ad","*   **Full-Year Turnaround:** The company returned to profitability for the year ended March 31, 2026, posting a consolidated profit of ₹39.44 Lacs, compared to a loss of ₹67.41 Lacs in the previous year.\n*   **Contrasting Q4 Loss:** Despite the annual profit, the company reported a consolidated net loss of ₹45.08 Lacs for the fourth quarter (Q4 FY26), raising questions about the sustainability of the turnaround.\n*   **Key Governance Vacancy (Red Flag):** The Company Secretary & Compliance Officer has resigned effective April 30, 2026, creating a critical vacancy in a key managerial and compliance role.\n*   **Unusual Meeting Time:** The Board Meeting to approve these results was noted to have occurred at the highly unusual time of 10:30 PM.",{"company_name":165,"filing_date":166,"filing_source":17,"headline":167,"id":168,"stock_code":169,"summary_text":170},"Shri Gang Industries & Allied Products Ltd","2026-05-07T23:11:40.462000","Board Approves Reclassification of Promoter Group","69fccf01c9cbead9b3c586c1","523309","*   The Board of Directors has approved the request to reclassify four individuals—Mr. Ajay Gupta, Mr. Shailesh Gupta, Mr. Siddharth Gupta, and Mr. Ramesh Gupta—from the 'Promoter & Promoter Group' to the 'Public' category.\n*   The rationale is that these individuals are not involved in the company's management or control, hold less than 10% of voting rights, and do not have any special rights or board positions.\n*   This reclassification is now subject to the approval of the stock exchange(s) and other regulatory bodies.\n*   The action will increase the company's public shareholding float and provides clarity that these individuals are no longer associated with the company's management.",{"company_name":172,"filing_date":173,"filing_source":9,"headline":174,"id":175,"stock_code":176,"summary_text":177},"ROUTE MOBILE LIMITED","2026-05-07T23:11:39.648000","Board Recommends Final Dividend","69fccef258d87443453a091c","ROUTE","*   The Board of Directors has recommended a Final Dividend of ₹ 2 per equity share for the financial year ended 31 March 2026.\n*   This dividend is subject to the approval of shareholders at the upcoming Annual General Meeting (AGM).\n*   The Record Date for dividend eligibility and the date of the AGM will be announced at a later time.",{"company_name":172,"filing_date":179,"filing_source":9,"headline":180,"id":181,"stock_code":176,"summary_text":182},"2026-05-07T23:11:39.461000","FY26 Results: Revenue Dips 3.7%, Profitability Improves","69fccf10890e096a6fc59207","- **Annual Revenue (FY26):** Declined by 3.7% year-over-year to ₹44,082 mn.\n- **Annual Profitability (FY26):** Adjusted PAT grew 6.7% year-over-year to ₹3,761 mn, with margins expanding.\n- **Dividend:** The Board has proposed a final dividend of ₹2 per share.\n- **Client Concern:** The number of top-tier clients (>$15M account size) decreased from 8 in FY25 to 5 in FY26.\n- **Operational Growth:** Billable transactions increased by 12.3% YoY to 174.9 billion.",{"company_name":172,"filing_date":184,"filing_source":9,"headline":185,"id":186,"stock_code":176,"summary_text":187},"2026-05-07T23:11:39.434000","FY26 Revenue & Profit Fall, But Margins Improve & Dividend Hiked","69fccf160c6b4fb98a923030","*   \u003Cb>FY26 Performance:\u003C\u002Fb> Revenue from Operations fell 3.66% YoY to ₹4,408 Cr, and Profit After Tax (PAT) declined 23.06% YoY to ₹257 Cr.\n*   \u003Cb>Strategic Shift:\u003C\u002Fb> Management attributes the revenue drop to a \"deliberate portfolio reshaping\" to focus on higher-margin services.\n*   \u003Cb>Profitability Focus:\u003C\u002Fb> Despite the top-line decline, FY26 Gross Margin improved to 22.9% (+210 bps YoY) and Q4 PAT surged 89.83% YoY.\n*   \u003Cb>FY27 Outlook & Dividend:\u003C\u002Fb> The company guided for \"mid to high single digit\" revenue growth and an increased dividend of ₹16.5 per share.",{"company_name":172,"filing_date":189,"filing_source":9,"headline":190,"id":191,"stock_code":176,"summary_text":192},"2026-05-07T23:11:39.401000","Key Leadership Appointments Announced","69fccef5abd16353d2ffb1f2","*   The company has appointed two new Senior Management Personnel and re-appointed its Internal Auditor, effective 07 May 2026.\n*   \u003Cb>Mr. Alyque Sequeira\u003C\u002Fb> has been appointed as \u003Cb>Executive Advisor to the CEO\u003C\u002Fb>. He is a CPaaS expert with nearly 20 years of experience, known for driving product-led growth.\n*   \u003Cb>Mr. Gaurav Jhunjunwala\u003C\u002Fb> joins as \u003Cb>AGM- Legal\u003C\u002Fb>, bringing over 14 years of experience in corporate legal advisory and contract management.\n*   \u003Cb>Mr. Nicolas Lecomte\u003C\u002Fb> has been re-appointed as the company's \u003Cb>Internal Auditor\u003C\u002Fb>.",{"company_name":194,"filing_date":195,"filing_source":9,"headline":196,"id":197,"stock_code":198,"summary_text":199},"JB Chemicals & Pharmaceuticals Limited","2026-05-07T23:11:39.373000","Schedules Q4 FY26 Earnings Call for Investors & Analysts","69fccef7a157653c663a1367","JBCHEPHARM","*   Financial results for the fourth quarter ended March 31, 2026, will be announced on **Monday, May 11, 2026**.\n*   An investor and analyst conference call to discuss the results is scheduled for **Tuesday, May 12, 2026, at 8:30 AM IST**.\n*   Senior management will be present to discuss the company's performance, strategy, and business developments.",{"company_name":201,"filing_date":202,"filing_source":17,"headline":203,"id":204,"stock_code":176,"summary_text":205},"Route Mobile Ltd","2026-05-07T23:06:40.486000","FY26 Results: Lower Revenue Offset by Strong Profit Growth","69fccdedec7f5de862c576ff","*   **Revenue Decline:** Full-year revenue for FY26 fell by 3.7% YoY to ₹44,082 mn. Q4 revenue also saw a 3.8% YoY decline.\n*   **Profitability Soars:** Despite lower sales, Adjusted PAT grew 6.7% for the full year and surged 34.6% YoY in Q4, driven by significant margin expansion across the board.\n*   **Client Risk:** The number of top-tier clients (with >₹15mn account size) decreased from 8 to 5 in FY26, indicating potential churn or reduced business from key accounts.\n*   **Dividend Proposed:** The Board has recommended a final dividend of ₹2 per share for the financial year 2025-26.\n*   **Cost Pressure:** Operating costs in Q4 increased by 10% YoY, driven by salary increments and a write-off of certain trade receivables.",{"company_name":201,"filing_date":207,"filing_source":17,"headline":208,"id":209,"stock_code":176,"summary_text":210},"2026-05-07T23:06:40.455000","Reports Mixed FY26 Results: Revenue Declines, Margins Improve","69fccdee58d87443453a0917","*   **FY26 Revenue from Operations** declined 3.66% YoY to ₹4,408.21 Cr.\n*   **Full-year Profit After Tax (PAT)** fell significantly by 23.06% YoY to ₹256.94 Cr.\n*   Despite lower revenue, **Gross Profit Margin** improved to 22.9% from 20.8% in FY25, which management attributes to a \"deliberate portfolio reshaping.\"\n*   The company is now part of **Proximus Group**, indicating a major corporate restructuring.\n*   Management provides **FY27 guidance** for mid-to-high single-digit revenue growth and an increased dividend of ₹16.5 per share.",{"company_name":212,"filing_date":213,"filing_source":17,"headline":214,"id":215,"stock_code":198,"summary_text":216},"JB Chemicals & Pharmaceuticals Ltd","2026-05-07T23:06:40.433000","Schedules Investor Call to Discuss Q4 FY26 Results","69fccdc9f43b112c8d9215a8","• A conference call for investors and analysts is scheduled for **Tuesday, May 12, 2026, at 8:30 a.m. IST**.\n• The call will discuss the financial results for the **fourth quarter ended March 31, 2026**.\n• The financial results will be officially announced a day prior, on **Monday, May 11, 2026**.\n• Senior management of the company will be present to address the call.",{"company_name":165,"filing_date":218,"filing_source":17,"headline":219,"id":220,"stock_code":169,"summary_text":221},"2026-05-07T23:06:40.403000","Positive Legal Update: High Court Stays Tax Order","69fccdcfecaa861d94922509","• The Allahabad High Court has granted an interim stay in the company's legal case against a tax order from UP tax authorities.\n• This stay temporarily suspends the enforcement and financial impact of the adverse tax order, which was issued under the Central Sales Tax Act and UP VAT Act.\n• The court's action provides temporary relief from a potential financial liability arising from the tax dispute.\n• This is considered a material positive development for shareholders, though the final outcome of the case is still pending.",{"company_name":172,"filing_date":223,"filing_source":9,"headline":224,"id":225,"stock_code":176,"summary_text":226},"2026-05-07T23:06:39.525000","Route Mobile Declares Final Dividend; Profitability Hit by ₹136 Cr Exceptional Loss","69fccdeb0c6b4fb98a92302a","- **FY26 Results:** Consolidated Revenue fell 3.66% to ₹4,408 Cr, while Profit After Tax (PAT) dropped sharply by 23.05% to ₹256.94 Cr.\n- **Exceptional Loss (Red Flag):** Profitability was heavily impacted by exceptional losses of ₹135.87 Cr due to vendor-related write-offs. The auditor highlighted this as an \"Emphasis of Matter\".\n- **Dividend Declared:** The Board recommended a final dividend of ₹2 per share, bringing the total dividend for FY26 to ₹11 per share.\n- **Segment Performance:** The Overseas segment's profit grew 15.23%, but the India segment's profit saw a steep decline of 38.14%.\n- **IPO Funds:** The company seeks to change the use of unutilized IPO funds of ₹65 Cr from \"Purchase of office premises\" to \"General Corporate purpose,\" subject to shareholder approval.",{"company_name":228,"filing_date":229,"filing_source":17,"headline":230,"id":231,"stock_code":232,"summary_text":233},"Parag Milk Foods Ltd","2026-05-07T23:01:40.753000","FY26 Results: Revenue Up 11%, Dividend Declared","69fcccceec7f5de862c576fb","PARAGMILK","*   \u003Cb>Financials (FY26 vs FY25):\u003C\u002Fb> Consolidated Revenue grew 11.23% to ₹3,817.50 Cr. Profit After Tax (PAT) increased by 13.69% to ₹135.05 Cr.\n*   \u003Cb>Dividend:\u003C\u002Fb> The Board has recommended a final dividend of ₹1.10 per share (11%), subject to shareholder approval.\n*   \u003Cb>Exceptional Item:\u003C\u002Fb> A one-time charge of ₹5.72 Cr (Consolidated) was recorded due to provisions for new Labour Codes.\n*   \u003Cb>Cash Flow Concern:\u003C\u002Fb> Net cash from operations decreased to ₹149.46 Cr from ₹212.04 Cr in the previous year, primarily due to a significant increase in inventories.\n*   \u003Cb>Equity Dilution:\u003C\u002Fb> The Board approved the allotment of 10,00,000 equity shares under the ESOP Scheme 2022, increasing the paid-up share capital.",{"company_name":201,"filing_date":235,"filing_source":17,"headline":236,"id":237,"stock_code":176,"summary_text":238},"2026-05-07T23:01:40.683000","FY26 Profit Down 23% on Large Write-offs; Final Dividend Announced","69fcccd05236ec998939fb27","*   **Profit Plummets:** Consolidated Net Profit for FY26 fell 23% YoY to ₹256.94 Cr, while revenue declined 3.66% to ₹4,408.21 Cr.\n*   **Exceptional Losses:** Profit was heavily impacted by exceptional write-offs totaling ₹135.87 Cr due to a failed vendor contract and a legal dispute, flagged by auditors as an \"Emphasis of Matter\".\n*   **Dividend Declared:** The Board has recommended a Final Dividend of ₹2\u002Fshare, bringing the total dividend for FY26 to ₹11\u002Fshare.\n*   **India Business Struggles:** The India segment's profit crashed by 38%, while the Overseas segment's profit grew by 15%.\n*   **Change in IPO Fund Use:** The company proposes to divert ₹65 Cr of unutilised IPO funds from an office purchase to \"General Corporate Purposes,\" subject to shareholder approval.",{"company_name":201,"filing_date":240,"filing_source":17,"headline":241,"id":242,"stock_code":176,"summary_text":243},"2026-05-07T23:01:40.598000","FY26 Results Show Profit Drop & ₹136 Cr Write-off; Final Dividend Announced","69fcccdac9cbead9b3c586b7","*   FY26 consolidated revenue fell 3.66% to ₹4,408 Cr, while Net Profit dropped 23% to ₹257 Cr.\n*   Booked a massive exceptional loss of ₹136 Cr from writing off advances paid to vendors, flagged by the auditor in an \"Emphasis of Matter\".\n*   The Board recommended a final dividend of ₹2 per share, bringing the total for the year to ₹11 per share.\n*   The India segment's profit margin compressed sharply from 11.8% to 7.4%, while the Overseas segment showed improved profitability.\n*   The company seeks to divert ₹65 Cr of IPO funds, originally for buying an office, to \"General Corporate purpose\", subject to shareholder approval.",{"company_name":153,"filing_date":245,"filing_source":17,"headline":246,"id":247,"stock_code":157,"summary_text":248},"2026-05-07T23:01:40.432000","FY26 Results: Profit Turnaround Marred by Major Red Flags","69fcccd1bf8f716f13ffa770","*   Reported a significant turnaround, with Revenue from Operations growing 1461% YoY to ₹11,591 Lacs and a Profit After Tax (PAT) of ₹39.44 Lacs (vs. a loss last year).\n*   \u003Cb>CRITICAL RED FLAG:\u003C\u002Fb> Despite the profit, Net Cashflow from Operating Activities was highly negative and worsened to ₹(257.92) Lacs, indicating profits are not being converted into actual cash.\n*   \u003Cb>GOVERNANCE CONCERNS:\u003C\u002Fb> A Non-Executive Director and the Company Secretary (KMP) resigned in quick succession. The Board Meeting to approve annual results and address these changes lasted only 10 minutes.\n*   \u003Cb>LACK OF TRANSPARENCY:\u003C\u002Fb> The company failed to provide a segment-wise performance breakdown, hindering a full analysis of its diverse business lines.",{"company_name":250,"filing_date":251,"filing_source":9,"headline":252,"id":253,"stock_code":232,"summary_text":254},"Parag Milk Foods Limited","2026-05-07T23:01:39.903000","FY26 Results: Profit Jumps 14%, Dividend Declared","69fcccce0c6b4fb98a923023","*   **Financials:** Consolidated revenue grew 11.2% to ₹3,817.5 Cr and Profit After Tax (PAT) rose 13.7% to ₹135.05 Cr for the financial year.\n*   **Dividend:** The Board has recommended a final dividend of ₹1.10 per share, subject to shareholder approval.\n*   **ESOP:** Approved the allotment of 10,00,000 equity shares to the employee stock option (ESOP) trust.\n*   **Exceptional Item:** Recorded a one-time exceptional charge of ₹5.72 Cr (Consolidated) due to provisions for new Labour Codes.\n*   **Audit Opinion:** The company received a clean (unmodified) audit opinion from its statutory auditors.\n*   **To Monitor:** Cash flow from operations decreased, primarily due to a significant increase in inventories.",{"company_name":7,"filing_date":256,"filing_source":9,"headline":257,"id":258,"stock_code":12,"summary_text":259},"2026-05-07T23:01:39.815000","FY26 Results: Profits Soar 237%, New CEO Appointed & Major ₹3,726 Cr Expansion Announced","69fcccd0890e096a6fc591f8","*   **Stellar Financials**: For FY26, Profit After Tax (PAT) surged 237.2% to ₹469.06 crore, while Revenue from Operations grew 40.6% to ₹4,803.43 crore.\n*   **Major Strategic Capex**: The Board approved a massive ₹3,726 crore investment to establish a 6 GW backward-integrated wafer and ingot facility in Tamil Nadu, aiming for completion by FY29.\n*   **New CEO Appointed**: Mr. Sameer Nagpal has been appointed as the new Whole-time Director & Chief Executive Officer, effective May 07, 2026, as part of a significant management shuffle.\n*   **Key Risks & Items to Watch**: The auditor's report highlighted over ₹2,013 million in contingent receivables subject to legal outcomes. The company also holds ₹9,617.85 million in unutilized IPO proceeds.",{"company_name":172,"filing_date":261,"filing_source":9,"headline":262,"id":263,"stock_code":176,"summary_text":264},"2026-05-07T23:01:39.735000","FY26 Results: Dividend Maintained, but Profits Hit by ₹136 Cr Write-off","69fcccbcabd16353d2ffb1dc","*   Consolidated Profit After Tax (PAT) declined 25% YoY to ₹239.02 Cr, largely due to significant exceptional items.\n*   The company reported exceptional write-offs totaling ₹135.87 Cr from an arbitration settlement and a vendor ceasing business.\n*   The Board has recommended a final dividend of ₹2 per share, bringing the total dividend for FY26 to ₹11 per share.\n*   The India segment's profit plummeted by 38.14%, while the Overseas segment's profit grew by 15.23%.\n*   A proposal was approved to change the use of ₹65 Cr in unutilized IPO proceeds to \"General Corporate purpose\", pending shareholder approval.",{"company_name":172,"filing_date":266,"filing_source":9,"headline":267,"id":268,"stock_code":176,"summary_text":269},"2026-05-07T23:01:39.727000","Declares ₹2 Final Dividend; Reports ₹136 Cr in Exceptional Losses","69fcccbfa157653c663a1352","*   The Board recommended a final dividend of **₹2 per share**, bringing the total dividend for FY26 to **₹11 per share**.\n*   Reported exceptional losses of **₹135.87 crores** from vendor-related write-offs, causing a 23% YoY drop in consolidated Net Profit to ₹256.94 crores.\n*   The Statutory Auditor issued an unmodified opinion but included an **\"Emphasis of Matter\"** to highlight the significance of these large write-offs.\n*   Seeks shareholder approval to change the use of **₹65 crores** in IPO proceeds from \"Purchase of office premises\" to \"General Corporate purpose.\"\n*   While the Overseas segment's profitability grew 15%, the **India segment's profit fell sharply by 38%**.",{"company_name":271,"filing_date":272,"filing_source":17,"headline":273,"id":274,"stock_code":275,"summary_text":276},"IIFL Capital Services Ltd","2026-05-07T22:56:40.855000","Fairfax Group Triggers Open Offer to Acquire Majority Stake","69fccbadecaa861d949224fb","IIFLCAPS","*   FIH Mauritius Investments Ltd (part of the Fairfax Group) has announced a mandatory open offer to acquire control of IIFL Capital Services Ltd.\n*   The offer is to acquire up to 26% of the company's shares at a price of **₹350 per share**, with a total consideration of up to ₹3,505.04 Crores.\n*   This is part of a larger transaction where the Fairfax Group will acquire a majority stake of at least 51% through a preferential issue and share purchase, becoming the new promoter.\n*   The acquirer has confirmed they **do not intend to delist** the company post-transaction.\n*   The deal is subject to multiple regulatory approvals, including from SEBI, IRDAI, and the Competition Commission of India (CCI).",{"company_name":201,"filing_date":278,"filing_source":17,"headline":279,"id":280,"stock_code":176,"summary_text":281},"2026-05-07T22:56:40.822000","FY26 Profit Hit by ₹136 Cr Write-off; Dividend Declared","69fccbb1ec7f5de862c576f5","*   **Profit Plummets:** Consolidated Profit After Tax for FY26 fell to ₹256.94 Cr from ₹333.93 Cr last year, with EPS dropping to ₹37.94 from ₹50.69.\n*   **Red Flag - Major Write-offs:** The profit was severely impacted by an exceptional loss of ₹135.87 Cr from two large write-offs related to a vendor dispute and another vendor ceasing operations.\n*   **Revenue Declines:** Consolidated revenue from operations decreased by 3.66% YoY to ₹4,408.21 Cr, with the India segment's profitability falling sharply by 38%.\n*   **Dividend Recommended:** The Board has recommended a final dividend of ₹2\u002Fshare, bringing the total dividend for FY26 to ₹11\u002Fshare.\n*   **Red Flag - IPO Funds:** The company proposes to change the use of ₹65 Cr in unutilized IPO funds from a specific property purchase to \"general corporate purpose,\" reducing transparency.",{"company_name":128,"filing_date":283,"filing_source":17,"headline":284,"id":285,"stock_code":12,"summary_text":286},"2026-05-07T22:56:40.780000","FY26 PAT Jumps 236%, Announces ₹3,726 Cr CAPEX for 6 GW Plant","69fccbb258d87443453a090b","*   **Stellar Financials:** For FY26, Profit After Tax (PAT) surged 236% to ₹4,704 crore, while Revenue from Operations grew 40% to ₹48,022 crore.\n*   **Major Strategic Investment:** The Board approved a landmark ₹3,726 crore capital expenditure to establish a 6 GW backward-integrated wafer and ingot facility in Tamil Nadu.\n*   **Key Management Changes:** Mr. Sameer Nagpal was appointed as the new CEO & Whole-time Director. Ms. Neha Agrawal resigned as Whole-time Director and was re-designated as SVP - Corporate Strategy.\n*   **Auditor's Emphasis of Matter:** The auditor highlighted two material risks: a disputed safeguard duty receivable of ₹1,485 crore and disputed customer receivables of ₹528 crore, both of which are under legal\u002Farbitration proceedings.\n*   **IPO Funds Status:** A significant balance of ₹9,618 crore from the recent IPO remains unutilised and is currently held in bank deposits.",{"company_name":128,"filing_date":288,"filing_source":17,"headline":289,"id":290,"stock_code":12,"summary_text":291},"2026-05-07T22:56:40.752000","Profit Soars 236%, Announces ₹3,726 Crore Expansion","69fccba95236ec998939fb23","*   Profit After Tax (PAT) surged \u003Cb>236%\u003C\u002Fb> YoY to ₹4,704 million for FY26.\n*   The Board approved a major capital expenditure of \u003Cb>₹3,726 crore\u003C\u002Fb> to build a new 6 GW wafer and ingot facility.\n*   Appointed \u003Cb>Mr. Sameer Nagpal\u003C\u002Fb> as the new CEO and Whole-time Director.\n*   Auditor's report highlights a potential risk of \u003Cb>₹2,013 million\u003C\u002Fb> from disputed receivables and duties, for which no provision has been made.",{"company_name":172,"filing_date":293,"filing_source":9,"headline":294,"id":295,"stock_code":176,"summary_text":296},"2026-05-07T22:56:39.341000","Profits Plunge on Massive Write-Offs; Dividend Declared","69fccba60c6b4fb98a92301c","*   Reported exceptional write-offs of ₹135.87 Cr due to vendor disputes and business cessation, flagged by auditors as an \"Emphasis of Matter\".\n*   Consolidated Net Profit (attributable to owners) dropped 25% YoY to ₹239.02 Cr, with Basic EPS falling to ₹37.94 from ₹50.69.\n*   The Board recommended a final dividend of ₹2 per share, bringing the total dividend for the year to ₹11 per share.\n*   A significant red flag was raised over the plan to re-allocate ₹65 Cr of IPO funds from \"office purchase\" to \"general corporate purpose\".\n*   The India segment's profitability saw a sharp decline of 38%, while the Overseas segment's profit grew by 15%.",{"company_name":298,"filing_date":299,"filing_source":9,"headline":300,"id":301,"stock_code":275,"summary_text":302},"IIFL Capital Services Limited","2026-05-07T22:56:39.246000","Fairfax Group to Acquire Controlling Stake via Open Offer","69fccba2abd16353d2ffb1d5","*   \u003Cb>Acquisition of Control:\u003C\u002Fb> FIH Mauritius Investments Ltd (part of the Fairfax Group) has launched a mandatory open offer to acquire a controlling stake in the company, aiming for at least 51% ownership.\n*   \u003Cb>Open Offer Details:\u003C\u002Fb> The offer is to acquire up to 26% of the share capital from public shareholders at a price of \u003Cb>₹350 per share\u003C\u002Fb>, with a total consideration of up to approx. ₹3,505 Crores.\n*   \u003Cb>Strategic Investment:\u003C\u002Fb> The transaction also includes a preferential issue of shares to the Acquirer worth approx. \u003Cb>₹2,000 Crores\u003C\u002Fb> at ₹350 per share, subject to shareholder approval.\n*   \u003Cb>New Promoter:\u003C\u002Fb> Upon completion, the Fairfax Group will be classified as the new 'promoter'. The existing promoters will continue as part of the promoter group.\n*   \u003Cb>Regulatory Approvals:\u003C\u002Fb> The deal is contingent on receiving approvals from various regulators, including SEBI, CCI, IRDAI, and others.",{"company_name":304,"filing_date":305,"filing_source":9,"headline":306,"id":307,"stock_code":308,"summary_text":309},"Kfin Technologies Limited","2026-05-07T22:56:39.236000","Kfin Tech Reports Mixed FY26 Results: Strong Revenue Growth, But Margin Pressure from Acquisition","69fccb99a157653c663a134b","KFINTECH","*   FY26 revenue grew a strong 19.3%, but Q4 performance was weak with a 6.3% sequential revenue decline due to market volatility and lower retail participation.\n*   Profitability was squeezed, with FY26 Core PAT growing only 6.2%. EBITDA margins were significantly compressed by the recent low-margin Ascent acquisition (which had an 8% EBITDA margin in Q4).\n*   The Issuer Solutions segment underperformed due to a \"mass exodus of retail investors,\" while the International business was the strongest growth driver.\n*   **FY27 Guidance:** Management projects strong 23-24% revenue growth but only ~10% PAT growth, signaling continued margin pressure in the year ahead.",{"company_name":311,"filing_date":312,"filing_source":17,"headline":313,"id":314,"stock_code":315,"summary_text":316},"Regency Fincorp Ltd","2026-05-07T22:51:41.598000","Earnings Call Audio Recording for Q4 & FY26 Now Available","69fcca4ebf8f716f13ffa763","540175","*   Regency Fincorp has published the audio recording of its earnings conference call held on May 7, 2026.\n*   The call discusses the financial results for the quarter and year ended March 31, 2026.\n*   This filing is a notification to inform stakeholders where to access the recording and does not contain financial data itself.\n*   Investors can access the recording via the link provided in the filing to hear management's discussion and analysis.",{"company_name":201,"filing_date":318,"filing_source":17,"headline":319,"id":320,"stock_code":176,"summary_text":321},"2026-05-07T22:51:41.552000","FY26 Results: Final Dividend Declared Despite 23% Drop in Net Profit","69fcca7d58d87443453a0905","*   \u003Cb>Profit Hit:\u003C\u002Fb> Consolidated Net Profit for FY26 fell 23% YoY to ₹256.9 Cr, with Basic EPS dropping to ₹37.94 from ₹50.69 in the previous year.\n*   \u003Cb>Major Red Flag:\u003C\u002Fb> Profit was heavily impacted by a one-time exceptional loss of ₹135.87 Cr due to an arbitration settlement write-off and a vendor advance write-off.\n*   \u003Cb>Segment Divergence:\u003C\u002Fb> The Overseas segment's profit grew by 15.2%, while the India segment's profit plummeted by 38.1%.\n*   \u003Cb>Shareholder Payout:\u003C\u002Fb> The Board recommended a final dividend of ₹2 per share, bringing the total dividend for FY26 to ₹11 per share.\n*   \u003Cb>Strategic Shift:\u003C\u002Fb> The company proposes to reallocate ₹65 Cr of IPO funds from a planned property purchase to \"General Corporate purpose,\" pending shareholder approval.",{"company_name":323,"filing_date":324,"filing_source":17,"headline":325,"id":326,"stock_code":327,"summary_text":328},"Gretex Corporate Services Ltd","2026-05-07T22:51:41.533000","FY26 Results: Dividend Declared, Raises ₹70 Cr via Warrants Amidst Cash Flow Concerns","69fcca79890e096a6fc591e4","543324","*   **Mixed Financials**: Standalone Profit After Tax (PAT) grew 4% to ₹1,300 Lakhs. However, consolidated operations reported a significant negative cash flow of ₹(3,105) Lakhs, driven by a 94% surge in inventory.\n*   **Dividend**: The Board has recommended a final dividend of ₹0.70 per share for the financial year 2025-26.\n*   **Fundraising & Control Shift**: Approved raising ~₹69.84 Crores by issuing 19.51 Lakh convertible warrants. The allottees will be re-categorized as the \"Promoter Group\" post-allotment, consolidating control.\n*   **Governance Red Flag**: The company's Secretarial Auditor (M\u002Fs RKN & Co) has resigned effective May 07, 2026. A new auditor has been appointed.",{"company_name":146,"filing_date":330,"filing_source":17,"headline":331,"id":332,"stock_code":150,"summary_text":333},"2026-05-07T22:51:41.395000","Shukra Pharma Pivots to Health-Tech Amid Auditor Change & Governance Flags","69fccaa2f43b112c8d921594","*   **Strategic Pivot:** Launched four new wholly-owned subsidiaries focused on Diabetes Tech, Healthtech, Robotics, and Wound Care, marking a significant diversification.\n*   **Auditor Resignation (Red Flag):** The company's statutory auditor, M\u002Fs. Maak & Associates, resigned mid-tenure before completing their term, a major governance concern. A new auditor has been appointed.\n*   **Promoter Funding & Dilution:** Approved a preferential issue of 46.43 lakh convertible warrants to promoters, indicating promoter confidence but causing future equity dilution for public shareholders.\n*   **Governance Lapses:** The filing contains a significant data error (identical DIN for two different directors) and reveals a history of penalties for delayed regulatory filings.",{"company_name":201,"filing_date":335,"filing_source":17,"headline":336,"id":337,"stock_code":176,"summary_text":338},"2026-05-07T22:51:41.358000","FY26 Results: Profit Dips 23% on Major Write-offs; Final Dividend Announced","69fcca77ecaa861d949224f5","*   \u003Cb>Profit & Revenue Decline:\u003C\u002Fb> Consolidated Net Profit for FY26 fell 23.06% YoY to ₹256.94 crores, while revenue declined by 3.66%.\n*   \u003Cb>Exceptional Loss:\u003C\u002Fb> The profit drop was primarily driven by exceptional write-offs totaling ₹135.87 crores due to vendor-related issues. The auditor has issued an \"Emphasis of Matter\" on this.\n*   \u003Cb>Segment Performance:\u003C\u002Fb> The India segment's profitability plunged by 38.14%, while the Overseas segment's profit grew by 15.23%.\n*   \u003Cb>Dividend Declared:\u003C\u002Fb> The Board recommended a final dividend of ₹2 per share, bringing the total dividend for FY26 to ₹11 per share.\n*   \u003Cb>Change in IPO Fund Use:\u003C\u002Fb> The company proposes to reallocate ₹65 crores, originally for an office purchase, to \"General Corporate purpose,\" subject to shareholder approval.\n*   \u003Cb>Management Change:\u003C\u002Fb> Mr. Alyque Sequeira has been appointed as Executive Advisor to the CEO.",{"company_name":340,"filing_date":341,"filing_source":17,"headline":342,"id":343,"stock_code":308,"summary_text":344},"KFin Technologies Ltd","2026-05-07T22:51:41.291000","FY26 Revenue Jumps 19%, Guides for Strong FY27 Growth Despite Margin Pressure","69fcca7f5236ec998939fb1d","*   \u003Cb>FY26 Performance:\u003C\u002Fb> Consolidated Revenue grew 19.3% year-over-year, while Core PAT increased by 6.2%.\n*   \u003Cb>Acquisition Impact:\u003C\u002Fb> The acquisition of Ascent Fund Solutions boosted revenue but significantly compressed margins, with the consolidated EBITDA margin dropping to 37% in Q4.\n*   \u003Cb>FY27 Guidance:\u003C\u002Fb> Management projects strong revenue growth of 23-24% but expects slower PAT growth of ~10%, signaling a period of strategic investment and continued margin pressure.\n*   \u003Cb>Growth Drivers:\u003C\u002Fb> The International business and Pension services are top performers, with Pensions growing 34% (3x the industry rate), successfully diversifying revenue away from the core domestic mutual fund segment.",{"company_name":346,"filing_date":347,"filing_source":9,"headline":348,"id":349,"stock_code":350,"summary_text":351},"Shakti Pumps (India) Limited","2026-05-07T22:51:39.148000","Recommends Final Dividend of ₹1 per Share","69fcca41a157653c663a1340","SHAKTIPUMP","*   The Board of Directors has recommended a **Final Dividend of ₹1 per equity share**.\n*   This is subject to shareholder approval at the upcoming Annual General Meeting (AGM).\n*   **Record Date**: 29 July 2026.\n*   **Payment Period**: 05 August 2026 to 04 September 2026 (if approved).",{"company_name":172,"filing_date":353,"filing_source":9,"headline":354,"id":355,"stock_code":176,"summary_text":356},"2026-05-07T22:51:39.147000","FY26 Results: Dividend Declared, But Profit Hit by ₹136 Cr Write-Off","69fcca6d0c6b4fb98a923015","*   **Financials:** Consolidated revenue for FY26 fell 3.66% to ₹4,408 Cr. Net profit for shareholders dropped 25% to ₹239 Cr, with EPS falling from ₹50.69 to ₹37.94.\n*   **Exceptional Loss:** Profit was heavily impacted by an exceptional loss of ₹135.87 Cr due to vendor-related write-offs, which was highlighted by the auditors as an \"Emphasis of Matter\".\n*   **Dividend:** The Board recommended a final dividend of ₹2\u002Fshare, bringing the total dividend for FY26 to ₹11\u002Fshare.\n*   **Segment Performance:** The Overseas segment showed strong profit growth (+15.23%), while the India segment's profit plummeted by 38.14%.\n*   **Red Flag - IPO Funds:** The company proposes to change the use of ₹65 Cr in unutilized IPO funds from \"office purchase\" to \"general corporate purposes\", pending shareholder approval.",{"company_name":358,"filing_date":359,"filing_source":17,"headline":360,"id":361,"stock_code":350,"summary_text":362},"Shakti Pumps India Ltd","2026-05-07T22:46:41.524000","Board Approves Re-appointment of Chairman & MD","69fcc937f43b112c8d92158e","*   The Board of Directors has approved the re-appointment of **Mr. Dinesh Patidar** as **Chairman cum Whole-time Director** and **Mr. Ramesh Patidar** as **Managing Director**.\n*   Both re-appointments are for a further term of **3 years**, effective from May 07, 2026.\n*   These appointments are subject to the approval of shareholders at the upcoming Annual General Meeting (AGM).\n*   The filing highlights a key family relationship: the re-appointed Chairman, Mr. Dinesh Patidar, is the brother of Mr. Sunil Patidar, a Whole Time Director on the board.",{"company_name":323,"filing_date":364,"filing_source":17,"headline":365,"id":366,"stock_code":327,"summary_text":367},"2026-05-07T22:46:41.506000","FY26 PAT Soars 1438%, Board Approves Dividend & ₹70 Cr Warrant Issue","69fcc94ebf8f716f13ffa75d","• \u003Cb>Stellar Profit Growth:\u003C\u002Fb> Consolidated Profit After Tax (PAT) for FY26 surged by 1438% to ₹27.9 Cr. Basic EPS jumped to ₹11.89 from ₹0.58 in the previous year.\n• \u003Cb>Dividend Declared:\u003C\u002Fb> The Board recommended a final dividend of ₹0.70 per share (7% on face value) for the financial year 2025-26.\n• \u003Cb>Major Capital Raise & Promoter Change:\u003C\u002Fb> Approved raising ~₹70 Crores via a preferential issue of warrants. The largest allottee, Ambition Tie-Up Private Limited, will be categorized under the Promoter Group post-allotment, signaling a significant ownership shift.\n• \u003Cb>Governance Red Flag:\u003C\u002Fb> The company's Secretarial Auditor, M\u002Fs. RKN & Co, has resigned with immediate effect. A new auditor has been appointed.",{"company_name":128,"filing_date":369,"filing_source":17,"headline":370,"id":371,"stock_code":12,"summary_text":372},"2026-05-07T22:46:41.389000","Posts Strong FY26 Results & Announces ₹3,726 Cr Capex Plan","69fcc95aec7f5de862c576e8","*   \u003Cb>Financials (FY26 vs FY25):\u003C\u002Fb> Revenue grew 40.28% to ₹48,022 million, while Profit After Tax (PAT) surged 236.42% to ₹4,704 million.\n*   \u003Cb>Major Capex:\u003C\u002Fb> The Board approved a ₹3,726 crore investment to set up a 6 GW backward-integrated wafer and ingot facility in Tamil Nadu, aiming for full integration.\n*   \u003Cb>Leadership Change:\u003C\u002Fb> Mr. Sameer Nagpal has been appointed as the new Whole-time Director and Chief Executive Officer (CEO).\n*   \u003Cb>Auditor's Red Flag:\u003C\u002Fb> While the opinion is clean (unmodified), the auditor highlighted two \"Emphasis of Matter\" items totaling over ₹2,013 million (~₹201 Cr) in potential write-offs from disputed receivables and duties.",{"company_name":146,"filing_date":374,"filing_source":17,"headline":375,"id":376,"stock_code":150,"summary_text":377},"2026-05-07T22:46:41.369000","FY26 Results: Strong Growth Clouded by Q4 Loss & Major Red Flag","69fcc96bc9cbead9b3c586a0","*   **Financials:** Full-year revenue grew 66.6% to ₹6,129.10 Lakhs, but the company reported a sharp net loss of ₹171.62 Lakhs in Q4 FY26, reversing from a profit in Q3.\n*   \u003Cb>MAJOR RED FLAG:\u003C\u002Fb> The company declared '0' total debt in a compliance filing, directly contradicting its balance sheet which shows borrowings of ₹5.02 Crores.\n*   **New Segment Issues:** The new \"Medtech\" segment, holding assets worth ₹12.68 Crores, generated zero revenue or profit in its first six months of operation.\n*   **Corporate Actions:** The Board recommended a final dividend of ₹0.01\u002Fshare and approved the allotment of 17.35 lakh shares to the Promoter Group upon warrant conversion.",{"company_name":379,"filing_date":380,"filing_source":17,"headline":381,"id":382,"stock_code":383,"summary_text":384},"Inventure Growth & Securities Ltd","2026-05-07T22:46:41.120000","Core Business Profit Collapses Amid Major Restructuring","69fcc957f35e30561cff96ff","INVENTURE","*   **Profitability Collapse:** The core Equity\u002FCommodity Broking segment's Profit Before Tax (PBT) plummeted by 84% year-over-year. Overall group PBT fell by 30% to ₹4.16 Cr for FY26.\n*   **Major Restructuring Planned:** The company is pursuing a complex scheme to merge four subsidiaries and then demerge its lending business. This is a material event highlighted by the auditors but is not yet complete.\n*   **Strategic Shift in Capital Use:** Funds from the 2024 Rights Issue, originally for new technology, have been re-allocated towards the Margin Trading Facility (MTF) and working capital, marking a significant change in strategy.\n*   **Unusual Income Item:** Reported profit for Q4 was boosted by a ₹62.35 Lakhs reversal of a provision previously made for alleged fraudulent transactions by a former employee.",{"company_name":358,"filing_date":386,"filing_source":17,"headline":387,"id":388,"stock_code":350,"summary_text":389},"2026-05-07T22:46:41.101000","[Appoints New Cost Auditor for FY 2026-27]","69fcc924abd16353d2ffb1bd","*   The Board of Directors approved the appointment of M\u002Fs. M.P. Turakhia & Associates as the Cost Auditor for the company.\n*   The appointment is for the Financial Year 2026-27.\n*   This action is in compliance with Section 148 of the Companies Act, 2013.\n*   The appointment is subject to the approval of shareholders at the ensuing Annual General Meeting (AGM).",{"company_name":201,"filing_date":391,"filing_source":17,"headline":392,"id":393,"stock_code":176,"summary_text":394},"2026-05-07T22:46:41.043000","FY26 Profit Dips on ₹136 Cr Write-off, Final Dividend at ₹2\u002Fshare","69fcc9505236ec998939fb18","*   📉 **Financials:** Consolidated Revenue fell 3.66% YoY to ₹4,408 Cr. Profit After Tax (PAT) attributable to owners dropped significantly to ₹239 Cr from ₹319 Cr in FY25.\n*   🚩 **Exceptional Loss:** Profit was heavily impacted by a one-time exceptional loss of **₹135.87 Cr** from two major vendor-related write-offs (an arbitration settlement and a vendor default).\n*   📊 **Segment Performance:** The India segment's profitability plummeted by 38%, while the Overseas segment's profit grew by a healthy 15%.\n*   💰 **Dividend:** The Board recommended a final dividend of **₹2.00 per share**. This brings the total dividend for FY26 to ₹11.00 per share.\n*   🔄 **Capital Allocation:** The company proposes to divert ₹65 Cr of unutilized IPO funds from \"Purchase of office premises\" to \"General Corporate purpose,\" subject to shareholder approval.",{"company_name":323,"filing_date":396,"filing_source":17,"headline":397,"id":398,"stock_code":327,"summary_text":399},"2026-05-07T22:46:41.037000","Increases Authorised Capital, Signals Potential Fundraising","69fcc92f58d87443453a08fc","*   The company has increased its Authorised Share Capital from ₹24.20 Crore to ₹26.50 Crore after receiving shareholder approval.\n*   This action amends the Capital Clause (V) of the company's Memorandum of Association (MOA).\n*   This is a strong indicator that the company may be planning to raise capital in the near future, which could lead to potential equity dilution for existing shareholders.",{"company_name":346,"filing_date":401,"filing_source":9,"headline":402,"id":403,"stock_code":350,"summary_text":404},"2026-05-07T22:46:39.747000","Key Leadership Re-appointed, New Auditors on Board","69fcc92ba157653c663a1332","• \u003Cb>Leadership Continuity Secured:\u003C\u002Fb> Mr. Dinesh Patidar (Chairperson) and Mr. Ramesh Patidar (Managing Director) have been re-appointed for a 3-year term, signaling stable top management.\n• \u003Cb>New Auditors Appointed:\u003C\u002Fb> M\u002Fs. M.P. Turakhia & Associates, an experienced firm, has been appointed as the new Cost Auditors for a 1-year term.\n• \u003Cb>Effective Date:\u003C\u002Fb> All changes are effective from May 7, 2026.",{"company_name":7,"filing_date":406,"filing_source":9,"headline":407,"id":408,"stock_code":12,"summary_text":409},"2026-05-07T22:46:39.722000","Posts 236% Profit Growth, Announces ₹3,726 Cr Expansion","69fcc93d890e096a6fc591da","*   Reports a 236% surge in Profit After Tax (PAT) to ₹4,704.21 million for FY26, with revenue growing by 40%.\n*   Approves a massive ₹3,726 crore capital expenditure to build a 6 GW backward-integrated wafer and ingot facility in Tamil Nadu.\n*   Appoints Mr. Sameer Nagpal as the new Whole-time Director and Chief Executive Officer (CEO), effective May 07, 2026.\n*   Auditor's report flags a key risk: over ₹2,000 million in receivables are contingent on legal outcomes, which could materially impact future profits.",{"company_name":172,"filing_date":411,"filing_source":9,"headline":412,"id":413,"stock_code":176,"summary_text":414},"2026-05-07T22:46:39.691000","FY26 Results: Dividend Declared, but Profit Hit by ₹136 Cr Write-Off","69fcc9460c6b4fb98a92300e","*   **Financial Performance:** FY26 revenue fell 3.66% to ₹4,408 Cr. Profit Before Tax dropped to ₹353 Cr from ₹426 Cr in FY25, primarily due to a large exceptional loss. Basic EPS declined to ₹37.94 from ₹50.69.\n*   **Major Red Flag:** The company booked an exceptional loss of **₹135.87 Cr** from writing off advances to vendors in its subsidiaries, raising serious concerns about operational risk controls.\n*   **Dividend Declared:** The Board recommended a final dividend of ₹2\u002Fshare, bringing the total dividend for FY 2025-26 to **₹11 per share**, subject to shareholder approval.\n*   **Segment Divergence:** The India segment's profitability plunged by **38.14%**, while the Overseas segment's profit grew by 15.23%, making it the key profit driver.\n*   **Use of IPO Funds:** The company seeks shareholder approval to divert **₹65 Cr** from unutilized IPO proceeds (originally for an office purchase) to \"General Corporate purpose\".\n*   **Management Changes:** Appointed Mr. Alyque Sequeira (ex-Vodafone, Paytm) as Executive Advisor to CEO and Mr. Gaurav Jhunjunwala as AGM-Legal.",{"company_name":323,"filing_date":416,"filing_source":17,"headline":417,"id":418,"stock_code":327,"summary_text":419},"2026-05-07T22:41:41.153000","Profit Soars 14x, Board Proposes Dividend & Major Capital Raise","69fcc81ef35e30561cff96f8","*   \u003Cb>FY26 Financials:\u003C\u002Fb> Net Profit (PAT) surged over 14x to ₹27.9 Cr from ₹1.8 Cr last year, despite a 31% decline in revenue. Basic EPS grew to ₹11.89 from ₹0.58.\n*   \u003Cb>Dividend Declared:\u003C\u002Fb> The Board recommended a final dividend of ₹0.70 per share (7% of face value) for the financial year 2026.\n*   \u003Cb>Capital Raise:\u003C\u002Fb> Approved raising ~₹69.85 Cr through a preferential issue of 19.51 lakh warrants at ₹358.00 per warrant.\n*   \u003Cb>New Promoter Entity:\u003C\u002Fb> Post-allotment, the largest allottee, Ambition Tie-Up Private Limited, will be categorized under the Promoter Group, indicating a significant change in ownership structure.\n*   \u003Cb>Red Flag:\u003C\u002Fb> The Secretarial Auditor (RKN & Co) resigned effective May 07, 2026, the same day the results were approved. A new auditor has been appointed.",{"company_name":201,"filing_date":421,"filing_source":17,"headline":422,"id":423,"stock_code":176,"summary_text":424},"2026-05-07T22:41:41.026000","Posts FY26 Results: Profit Hit by ₹136 Cr Write-off, Declares Dividend","69fcc82cbf8f716f13ffa757","*   **Profitability Decline**: Consolidated Profit After Tax for FY26 fell to ₹256.94 Cr from ₹333.93 Cr in FY25, primarily due to an exceptional loss of ₹135.87 Cr from write-offs in subsidiaries.\n*   **Revenue Performance**: Consolidated Revenue from Operations declined by 3.66% year-over-year to ₹4,408.21 Cr.\n*   **Dividend Declared**: The Board recommended a final dividend of ₹2.00 per share. The total dividend for the year aggregates to ₹11.00 per share.\n*   **Segment Performance**: The Overseas segment's profit grew by 15.23%, while the India segment's profit saw a sharp decline of 38.14%.\n*   **Red Flag**: Auditors issued an unmodified opinion but included an \"Emphasis of Matter\" highlighting the two large write-offs totaling ₹135.87 Cr, which points to significant operational risks.\n*   **Use of Funds**: The Board proposed changing the use of ₹65 Cr from unutilized IPO proceeds from \"Purchase of office\" to \"General Corporate purpose,\" subject to shareholder approval.",{"company_name":146,"filing_date":426,"filing_source":17,"headline":427,"id":428,"stock_code":150,"summary_text":429},"2026-05-07T22:41:41.011000","Fund Use Update Reveals Major Discrepancies","69fcc814ec7f5de862c576e3","\u003Cul>\n    \u003Cli>The company confirms \u003Cb>no deviation\u003C\u002Fb> in the use of ₹3.94 crore raised from its preferential issue for the quarter ended March 31, 2026.\u003C\u002Fli>\n    \u003Cli>\u003Cb>Red Flag:\u003C\u002Fb> A major price discrepancy was noted. The filing states an issue price of Re. 1, but the total amount implies a price of \u003Cb>₹34 per warrant\u003C\u002Fb>.\u003C\u002Fli>\n    \u003Cli>\u003Cb>Red Flag:\u003C\u002Fb> The document incorrectly uses the terms \"Preferential issue\" and \"Rights issue\" interchangeably, raising concerns about reporting accuracy.\u003C\u002Fli>\n    \u003Cli>The funds were raised as the first 25% tranche for an issue of 46.43 lakh convertible warrants.\u003C\u002Fli>\n\u003C\u002Ful>",{"company_name":431,"filing_date":432,"filing_source":9,"headline":433,"id":434,"stock_code":435,"summary_text":436},"Bajaj Finserv Limited","2026-05-07T22:41:39.403000","Q4 FY26: Underlying Profit Jumps 24% Despite Muted Headline Figures; Completes Allianz Stake Buyback","69fcc823ecaa861d949224e1","BAJAJFINSV","*   **Adjusted Performance:** Consolidated Profit After Tax (PAT) grew 24% YoY when adjusted for temporary Mark-to-Market (MTM) losses. Reported PAT growth was 5%.\n*   **Strategic Buyback:** The company completed the buyback of Allianz's stake in both its general and life insurance subsidiaries, making them 100% owned by the Bajaj Group.\n*   **Segment Highlights:** Bajaj Life Insurance was a top performer with 78% PAT growth. In contrast, Bajaj Finserv Direct (Markets) saw a 26.4% revenue decline, attributed to a planned system migration.\n*   **Core Business Growth:** Bajaj Finance Ltd. continued its strong trajectory with a 22% increase in Assets Under Management (AUM) and stable asset quality.\n*   **Management Outlook:** The underlying performance of all businesses is strong. Management expects the new ventures (Health, Markets, AMC) to reach break-even within the next few years.",{"company_name":438,"filing_date":439,"filing_source":9,"headline":440,"id":441,"stock_code":383,"summary_text":442},"Inventure Growth & Securities Limited","2026-05-07T22:41:39.346000","FY26 Results Show Performance Dip; Major Restructuring Ahead","69fcc82da157653c663a132d","*   A major corporate restructuring is underway, involving the merger of 4 subsidiaries and the demerger of its lending business. The plan is pending approval.\n*   The Financing segment reported a significant loss of ₹381.82 Lakhs (vs. a profit of ₹583.31 Lakhs last year), and profit from the core Broking segment fell sharply.\n*   FY26 profit was significantly boosted by a one-time exceptional income of ₹61.56 Lakhs from the reversal of a provision related to a past fraud case.\n*   The company re-allocated funds from its 2024 Rights Issue, shifting focus from technology development to expanding its Margin Trading Facility (MTF) and working capital.\n*   Consolidated revenue from operations for FY26 fell to ₹5,101.34 Lakhs from ₹6,240.88 Lakhs in FY25.",{"company_name":172,"filing_date":444,"filing_source":9,"headline":445,"id":446,"stock_code":176,"summary_text":447},"2026-05-07T22:41:39.343000","FY26 Results: Profit Hit by ₹136 Cr Write-Offs; Proposes Change in IPO Fund Use","69fcc821890e096a6fc591d4","*   Consolidated Profit After Tax fell 25% YoY to ₹239 Cr, heavily impacted by exceptional write-offs of ₹136 Cr related to vendor disputes and advances.\n*   The Board recommended a final dividend of ₹2\u002Fshare, bringing the total dividend for FY26 to ₹11 per share.\n*   The company proposes to re-allocate ₹65 Cr of unutilized IPO funds from 'purchasing an office' to 'General Corporate Purpose', subject to shareholder approval.\n*   India segment profitability dropped sharply by 38%, while the Overseas segment's profit grew over 15%.\n*   Auditors issued an unmodified opinion but added an 'Emphasis of Matter' paragraph highlighting the significant write-offs.",{"company_name":449,"filing_date":450,"filing_source":9,"headline":451,"id":452,"stock_code":453,"summary_text":454},"NRB Bearing Limited","2026-05-07T22:41:39.212000","FY26 Profits Surge, Announces Major Expansion into Aerospace & New JV","69fcc81dabd16353d2ffb1b4","NRBBEARING","*   Consolidated FY26 Profit After Tax (PAT) surged 77% to ₹145.6 Cr, with revenue growing 11.4% to ₹1,335 Cr.\n*   Declared a 3rd interim dividend of ₹2.25 per share. The total dividend for FY26 stands at ₹7.95 per share.\n*   Announced strategic entry into the aerospace sector by acquiring a precision components manufacturer, with an investment of up to ₹37.5 Cr.\n*   Approved a Joint Venture with Italy's Unitec S.r.L. to manufacture a new range of bearings, investing up to ₹67 Cr.\n*   Planned capex of up to ₹40 Cr to acquire land for a 17-25% capacity expansion, citing a robust order book for FY27-28.\n*   Disclosed a FEMA non-compliance with ₹21.8 Cr in overdue export payments, which poses a potential penalty risk.",{"company_name":346,"filing_date":456,"filing_source":9,"headline":457,"id":458,"stock_code":350,"summary_text":459},"2026-05-07T22:41:39.183000","Key Leadership Re-Appointed for Three-Year Term","69fcc80a0c6b4fb98a922ffc","*   The Board of Directors has approved the re-appointment of **Mr. Dinesh Patidar** as Chairman cum Whole-time Director for a term of 3 years.\n*   The Board has also approved the re-appointment of **Mr. Ramesh Patidar** as Managing Director for a term of 3 years.\n*   Both appointments are effective from May 07, 2026, and are subject to shareholder approval at the next Annual General Meeting (AGM).\n*   The filing notes that the Chairman, Mr. Dinesh Patidar, is the brother of another Whole-time Director, highlighting the family-managed nature of the enterprise.",{"company_name":146,"filing_date":461,"filing_source":17,"headline":462,"id":463,"stock_code":150,"summary_text":464},"2026-05-07T22:36:41.001000","FY26 Results: Revenue Jumps 67%, Dividend Declared Amid Reporting Concerns","69fcc6efc9cbead9b3c58690","*   \u003Cb>FY26 Financials:\u003C\u002Fb> Consolidated revenue surged by 66.6% YoY to ₹6,129.10 Lakhs, with a net profit of ₹2,205.84 Lakhs.\n*   \u003Cb>Dividend Declared:\u003C\u002Fb> The Board recommended a final dividend of ₹0.01 per share (1%), subject to shareholder approval.\n*   \u003Cb>Capital Infusion:\u003C\u002Fb> Promoters converted warrants, infusing ₹4.42 Crore into the company and increasing their stake to 18.48%.\n*   \u003Cb>Strategic Diversification:\u003C\u002Fb> The company is expanding into MedTech with a new segment and four subsidiaries, though the new segment reported zero revenue.\n*   \u003Cb>🚨 RED FLAGS:\u003C\u002Fb> The analysis flags major concerns, including unusual segment reporting and negative capital employed in the core Pharmaceutical business, questioning financial transparency.",{"company_name":323,"filing_date":466,"filing_source":17,"headline":467,"id":468,"stock_code":327,"summary_text":469},"2026-05-07T22:36:40.978000","Reports Strong FY26 Profit, Announces Dividend & ₹70 Cr Fundraise","69fcc6e3f35e30561cff96f3","*   \u003Cb>Financials:\u003C\u002Fb> Reports a significant turnaround with a full-year net profit of ₹27.9 Cr in FY26, up from ₹1.8 Cr in FY25.\n*   \u003Cb>Dividend:\u003C\u002Fb> The Board has recommended a final dividend of ₹0.70 per share.\n*   \u003Cb>Fundraising:\u003C\u002Fb> Approved raising approx. ₹69.84 Crores through a preferential issue of convertible warrants.\n*   \u003Cb>Key Development:\u003C\u002Fb> The allottees of the new warrants will be re-categorized as the \"Promoter Group\" post-allotment, signaling a major change in the company's ownership structure.\n*   \u003Cb>Governance Alert:\u003C\u002Fb> The company's Secretarial Auditor resigned with immediate effect on the day of the board meeting.",{"company_name":449,"filing_date":471,"filing_source":9,"headline":472,"id":473,"stock_code":453,"summary_text":474},"2026-05-07T22:36:39.402000","Posts 77% Profit Growth, Declares Dividend & Announces Major Expansion","69fcc6e4a157653c663a1328","*   Reports a 76.9% YoY increase in Profit After Tax (PAT) for FY26, reaching ₹14,563 Lakhs.\n*   The Board has declared a 3rd interim dividend of ₹2.25 per share (112.5% of face value).\n*   Announces strategic entry into the aerospace components industry via a new subsidiary and a new Joint Venture for manufacturing advanced bearings.\n*   Approves land acquisition of up to ₹40 Crores for a significant capacity expansion of 17-25% to meet a robust order book for FY27 & FY28.",{"company_name":476,"filing_date":477,"filing_source":17,"headline":478,"id":479,"stock_code":435,"summary_text":480},"Bajaj Finserv Ltd","2026-05-07T22:31:41.071000","Q4 PAT Rises 5%; Core Profit Jumps 24% Excluding Market Impact","69fcc5d7ec7f5de862c576d9","*   Consolidated Profit After Tax (PAT) grew 5% to ₹2,539 Cr. Excluding temporary market-related losses in the insurance business, adjusted PAT growth was a strong 24%.\n*   \u003Cb>Top Performers:\u003C\u002Fb> Bajaj Finance delivered robust results with PAT of ₹5,464 Cr. Bajaj Life Insurance saw PAT jump 78% with a 2.4% expansion in new business margins.\n*   \u003Cb>Challenged Segments:\u003C\u002Fb> General Insurance growth was muted due to a tactical reduction in unprofitable business. Bajaj Markets reported a planned 26% revenue dip from a system migration, with recovery expected.\n*   \u003Cb>Strategic Move:\u003C\u002Fb> Completed the buyback of Allianz's stake in both insurance subsidiaries, making them 100% Bajaj-owned. This is expected to enhance future returns.\n*   \u003Cb>Outlook & New Ventures:\u003C\u002Fb> Management targets break-even for Bajaj Markets by end of FY27 and for Bajaj Finserv Health in ~24 months. New businesses in Wealth Management and Alternatives are being established.",{"company_name":358,"filing_date":482,"filing_source":17,"headline":483,"id":484,"stock_code":350,"summary_text":485},"2026-05-07T22:31:41.062000","FY26 Results: Revenue Rises, Profitability Slips; ₹1 Dividend Recommended","69fcc5bfc9cbead9b3c58689","\u003Cul>\n\u003Cli>\u003Cb>FY26 Financials:\u003C\u002Fb> Consolidated Revenue from Operations grew 7.47% YoY to ₹2,722.45 Cr. However, Profit Before Tax (PBT) declined 35.38% YoY to ₹359.15 Cr.\u003C\u002Fli>\n\u003Cli>\u003Cb>Performance Driver:\u003C\u002Fb> The profit decline was primarily driven by a 31.85% drop in profitability in the core India segment. In contrast, the Overseas Subsidiaries segment saw strong revenue growth of 32.61%.\u003C\u002Fli>\n\u003Cli>\u003Cb>Dividend:\u003C\u002Fb> The Board has recommended a final dividend of \u003Cb>₹1.00 per equity share\u003C\u002Fb> for FY26, subject to shareholder approval.\u003C\u002Fli>\n\u003Cli>\u003Cb>Capital Raise:\u003C\u002Fb> The company successfully raised \u003Cb>₹292.60 crores\u003C\u002Fb> via a Qualified Institutional Placement (QIP), strengthening its balance sheet for future growth.\u003C\u002Fli>\n\u003Cli>\u003Cb>Leadership Continuity:\u003C\u002Fb> The Board approved the re-appointment of Mr. Dinesh Patidar (Chairman) and Mr. Ramesh Patidar (Managing Director) for a further term of 3 years.\u003C\u002Fli>\n\u003C\u002Ful>",{"company_name":449,"filing_date":487,"filing_source":9,"headline":488,"id":489,"stock_code":453,"summary_text":490},"2026-05-07T22:31:40.094000","Posts 77% Profit Growth, Enters Aerospace & Declares Dividend","69fcc5c6a157653c663a1323","*   \u003Cb>Strong Financials:\u003C\u002Fb> Consolidated Profit After Tax (PAT) surged by 77% to ₹14,563 Lakhs for FY26, with revenue growing 11.4% to ₹133,515 Lakhs.\n*   \u003Cb>Shareholder Payout:\u003C\u002Fb> Declared a 3rd interim dividend of ₹2.25 per share. The total dividend for FY26 stands at ₹7.95 per share.\n*   \u003Cb>Aerospace Entry:\u003C\u002Fb> Announced the acquisition of M\u002Fs Mahant Tool Room for ₹2,750 Lakhs, marking a strategic entry into manufacturing precision components for the aerospace industry.\n*   \u003Cb>New Joint Venture:\u003C\u002Fb> Partnered with Unitec S.r.L. of Italy to manufacture Cylindrical Roller Bearings, with an investment of up to ₹67 Crores.\n*   \u003Cb>Major Expansion:\u003C\u002Fb> Plans to invest up to ₹40 Crores to acquire land for a 17-25% increase in production capacity, citing a \"robust orderbook for FY 27 and FY 28\".\n*   \u003Cb>Red Flag:\u003C\u002Fb> The filing highlights a regulatory risk with overdue export receivables of ₹2,182 lakhs pending settlement under FEMA regulations.",{"company_name":449,"filing_date":492,"filing_source":9,"headline":493,"id":494,"stock_code":453,"summary_text":495},"2026-05-07T22:31:40.042000","Declares Interim Dividend for Shareholders","69fcc59a890e096a6fc591c4","*   The Board of Directors has declared an **Interim Dividend of ₹2.25 per equity share** for the financial year 2025-26.\n*   The record date to determine shareholder eligibility for the dividend has been fixed as **13 May 2026**.",{"company_name":346,"filing_date":497,"filing_source":9,"headline":498,"id":499,"stock_code":350,"summary_text":500},"2026-05-07T22:31:40.030000","Board Meeting Highlights: FY26 Results Approved & Dividend Recommended","69fcc59babd16353d2ffb1a5","*   The Board has approved the Audited Financial Results for the quarter and year ended March 31, 2026.\n*   A final dividend of **Rs. 1\u002F- per Equity Share** has been recommended, subject to shareholder approval.\n*   The record date for the dividend is set for **Wednesday, July 29, 2026**.\n*   Approved the re-appointment of Mr. Dinesh Patidar as Chairman and Mr. Ramesh Patidar as Managing Director for a term of 3 years.\n*   The 31st Annual General Meeting (AGM) will be held on **Wednesday, August 5, 2026**.\n*   Appointed M\u002Fs. M.P. Turakhia & Associates as the Cost Auditor for the Financial Year 2026-27.",{"company_name":146,"filing_date":502,"filing_source":17,"headline":503,"id":504,"stock_code":150,"summary_text":505},"2026-05-07T22:26:41.231000","FY26 Results, Dividend & Promoter Share Allotment","69fcc494bf8f716f13ffa744","*   **Financials:** The company reported a Consolidated Net Profit of ₹2,205.84 Lakhs for the financial year ended March 31, 2026. The core \"Shukra Pharmaceutical\" segment remains the sole revenue generator.\n*   **Dividend:** The Board has recommended a Final Dividend of ₹0.01 per equity share (1%) for FY26, subject to shareholder approval.\n*   **Warrant Conversion:** Allotted 17,35,000 equity shares to the Promoter group upon conversion of warrants, raising ₹4.42 Crore. This has increased the promoter group's stake from 18.17% to 18.48%.\n*   **Strategic Diversification:** The new \"Shukra MedTech\" segment, launched in Oct 2025, holds significant assets (₹1,268.49 Lakhs) but is currently in a pre-revenue phase with zero income reported.\n*   **Key Considerations:** 29,08,000 warrants remain outstanding, indicating potential for further equity dilution. The company also reported taking a loan from its Managing Director.",{"company_name":507,"filing_date":508,"filing_source":17,"headline":509,"id":510,"stock_code":511,"summary_text":512},"Ugro Capital Ltd","2026-05-07T22:26:41.135000","FY26 Sustainability Report: High Attrition & Related Party Deals in Focus","69fcc4a0ec7f5de862c576d4","UGROCAP","*   **Material Related Party Investments:** Investments in related parties constituted 86.29% of total investments made in FY26, a significant increase from Nil in the prior year.\n*   **High Employee Turnover:** The attrition rate for permanent employees remained high at 31% in FY26, following a trend of 29% in FY25 and 39% in FY24.\n*   **Governance Gap:** The company disclosed that it does not have a dedicated Board committee or a specific Director responsible for decision-making on sustainability issues.\n*   **Reduced Training:** Human rights training for employees dropped sharply to 52% in FY26 from 96% in the previous year.\n*   **Voluntary CSR & Green Finance:** Despite not being required to, the company voluntarily spent ₹3.95 Lakhs on CSR and is focusing on green finance for sectors like EVs and solar.",{"company_name":514,"filing_date":515,"filing_source":9,"headline":516,"id":517,"stock_code":327,"summary_text":518},"Gretex Corporate Services Limited","2026-05-07T22:26:39.879000","Seeks Shareholder Approval for Capital Raise & Warrant Issue","69fcc466a157653c663a131c","*   The company is seeking shareholder approval via postal ballot for two key resolutions.\n*   **Proposal 1:** To increase the Authorized Share Capital to ₹26.50 crore.\n*   **Proposal 2:** To issue fully convertible equity warrants on a preferential basis to raise funds.\n*   **Impact:** The move will bring in capital but may lead to equity dilution for existing shareholders upon conversion of the warrants.\n*   **Voting Period:** E-voting is open from May 8, 2026, to June 6, 2026.",{"company_name":520,"filing_date":521,"filing_source":9,"headline":522,"id":523,"stock_code":524,"summary_text":525},"Oswal Agro Mills Limited","2026-05-07T22:26:39.840000","CEO & Whole-time Director Resigns with Immediate Effect","69fcc46cabd16353d2ffb19d","OSWALAGRO","• Mrs. Shreya Choudhary has resigned from her positions as Chief Executive Officer (CEO) and Whole-time Director.\n• The resignation is effective immediately as of May 07, 2026.\n• The stated reason for the departure is \"unavoidable personal reasons.\"\n• The immediate nature of the resignation is a significant red flag, as it deviates from the standard practice of a planned transition.",{"company_name":507,"filing_date":527,"filing_source":17,"headline":528,"id":529,"stock_code":511,"summary_text":530},"2026-05-07T22:21:41.367000","FY26 Highlights: Acquisitions Fuel Growth, Strategy Shifts to High-Yield","69fcc3c85236ec998939faff","*   \u003Cb>Financial Performance (FY26 Consolidated):\u003C\u002Fb> Achieved a total AUM of ₹15,334 Cr, Revenue of ₹2,021 Cr, and PAT of ₹175 Cr.\n*   \u003Cb>Major Acquisitions:\u003C\u002Fb> Completed two significant acquisitions, making Profectus Capital (for ₹1,399 Cr) and Datasigns Technologies ('MyShubhLife') wholly-owned subsidiaries.\n*   \u003Cb>Strategic Pivot:\u003C\u002Fb> Initiated a major realignment to focus on high-yield segments like Emerging Market Loans and Embedded Merchant Finance, while de-prioritizing lower-yield businesses.\n*   \u003Cb>Corporate Restructuring:\u003C\u002Fb> The Board has approved a scheme to merge the newly acquired Profectus Capital with UGRO Capital, effective 01 April 2026.\n*   \u003Cb>Leadership Changes:\u003C\u002Fb> Appointed a new CEO (Mr. Anuj Pandey) and CFO (Ms. Shilpa Bhatter) during the year.\n*   \u003Cb>Credit Rating Upgrade:\u003C\u002Fb> India Ratings upgraded the company's rating to 'IND A+' with a 'Positive' outlook.",{"company_name":358,"filing_date":532,"filing_source":17,"headline":533,"id":534,"stock_code":350,"summary_text":535},"2026-05-07T22:21:41.307000","FY26 Results: Revenue Rises 7%, but Profit Plummets 37% on Margin Pressure","69fcc38af43b112c8d921573","*   **Profitability Concern:** For the year ended March 31, 2026, consolidated revenue grew 7.2% to ₹2,698 Cr, but Profit After Tax (PAT) fell sharply by 37% to ₹258 Cr.\n*   **Margin Collapse:** The profit decline was driven by a significant increase in costs, with materials consumed up 24.3% and employee expenses up 39.6% year-over-year.\n*   **Core Business Struggles:** The India segment, which accounts for over 96% of revenue, saw its profitability decline by 31.8%, overshadowing strong growth in the smaller overseas segment.\n*   **Capital & Dividend:** The company successfully raised ₹292.60 Cr via a Qualified Institutional Placement (QIP) in July 2025. The Board has recommended a final dividend of ₹1.00 per share.\n*   **Key Red Flag:** The stark contrast between revenue growth and a steep profit decline highlights a major risk in the company's ability to manage costs and pass them on to customers.",{"company_name":537,"filing_date":538,"filing_source":17,"headline":539,"id":540,"stock_code":524,"summary_text":541},"Oswal Agro Mills Ltd","2026-05-07T22:21:41.102000","CEO & Whole-time Director Resigns","69fcc348bf8f716f13ffa73d","*   Mrs. Shreya Choudhary has resigned from her positions as Chief Executive Officer (CEO) and Whole-time Director.\n*   The resignation is effective immediately, as of May 07, 2026.\n*   The stated reason is \"unavoidable personal reasons.\"\n*   This sudden departure creates a leadership vacuum and potential uncertainty for the company's strategic direction.",{"company_name":346,"filing_date":543,"filing_source":9,"headline":544,"id":545,"stock_code":350,"summary_text":546},"2026-05-07T22:21:39.480000","FY26 Results: Revenue Grows 7%, but Profit Plummets 37%","69fcc379abd16353d2ffb196","• \u003Cb>Financials:\u003C\u002Fb> Consolidated revenue for FY26 grew 7.5% YoY to ₹2,722.45 Crores, but Profit After Tax (PAT) declined sharply by 36.9% to ₹257.58 Crores.\n• \u003Cb>Dividend Declared:\u003C\u002Fb> The Board has recommended a final dividend of ₹1.00 per equity share for the financial year 2025-26.\n• \u003Cb>Capital Raise:\u003C\u002Fb> The company successfully raised ₹292.60 Crores through a Qualified Institutional Placement (QIP) to fund growth.\n• \u003Cb>Red Flags:\u003C\u002Fb> The results highlight significant margin pressure, a sharp increase in borrowings, and rising trade receivables, indicating potential working capital stress.\n• \u003Cb>Management Update:\u003C\u002Fb> The Board approved the re-appointment of the Chairman and the Managing Director for a further 3-year term, ensuring leadership continuity.",{"company_name":548,"filing_date":549,"filing_source":17,"headline":550,"id":551,"stock_code":453,"summary_text":552},"NRB Bearings Ltd","2026-05-07T22:16:42.050000","Posts 77% Profit Growth, Declares Dividend & Enters Aerospace Sector","69fcc233bf8f716f13ffa735","*   \u003Cb>Strong Financials:\u003C\u002Fb> Consolidated Profit After Tax (PAT) for FY26 surged by 77% YoY to ₹14,563 lakhs, with revenue growing 11.4%.\n*   \u003Cb>Dividend Declared:\u003C\u002Fb> The Board announced a 3rd interim dividend of ₹2.25 per share. No final dividend will be recommended for FY26.\n*   \u003Cb>Aerospace Entry:\u003C\u002Fb> The company is strategically diversifying into the aerospace and defence sector by investing up to ₹37.5 Crores in its subsidiary, MTRPL.\n*   \u003Cb>Major Capex:\u003C\u002Fb> Approved a ₹40 Crore investment for land acquisition to expand capacity by 17-25%, driven by a \"robust orderbook for FY27 & FY28\".\n*   \u003Cb>Key Risk:\u003C\u002Fb> Disclosed a FEMA compliance issue with ₹2,182 lakhs in overdue overseas receivables, which the company is working to resolve.",{"company_name":554,"filing_date":555,"filing_source":17,"headline":556,"id":557,"stock_code":558,"summary_text":559},"Ishwarshakti Holdings & Traders Ltd","2026-05-07T22:16:42.017000","Board Shake-up: Two Directors Resign","69fcc21ff43b112c8d92156b","506161","*   Mr. Vivek Seksaria and Mr. Yashasvi Seksaria have resigned from their positions as Directors, effective March 31, 2026.\n*   Consequently, Mr. Yashasvi Seksaria also ceases to be a member of the Audit Committee.\n*   The reason cited for both resignations is \"personal and unavoidable circumstances\".\n*   **Key Red Flag:** The company disclosed these resignations on May 07, 2026, a delay of over one month, which is a potential violation of SEBI's 24-hour disclosure rule.",{"company_name":507,"filing_date":561,"filing_source":17,"headline":562,"id":563,"stock_code":511,"summary_text":564},"2026-05-07T22:16:41.994000","FY26 Report: A Year of Transformation with Key Acquisitions & Strategic Pivot","69fcc299ecaa861d949224c9","*   \u003Cb>Financials:\u003C\u002Fb> Consolidated AUM grew 27.8% YoY to ₹15,334 Cr, with a Profit After Tax of ₹175 Cr for FY26.\n*   \u003Cb>Strategic Pivot:\u003C\u002Fb> Announced a major shift to exit low-yield segments (e.g., Supply Chain Financing) and focus on high-growth core businesses: Emerging Market Loans and Embedded Merchant Finance.\n*   \u003Cb>Key Acquisitions:\u003C\u002Fb> Acquired Profectus Capital (for ₹1,399 Cr) and Datasigns Technologies ('MyShubhLife'). The board has approved the merger of Profectus with Ugro, effective April 1, 2026 (subject to approval).\n*   \u003Cb>Segment Highlight:\u003C\u002Fb> Embedded Merchant Finance was the top performer, with AUM growing 207% to ₹2,280 Cr and the highest ROI at 26.1%.\n*   \u003Cb>Capital & Outlook:\u003C\u002Fb> Raised over ₹915 Cr in capital (Rights Issue & Preferential Allotment). Management guides for no further equity dilution until FY29.\n*   \u003Cb>Rating Upgrade:\u003C\u002Fb> India Ratings upgraded its outlook on the company's debt from 'Stable' to 'Positive', citing a stronger business profile post-acquisitions.",true,100,1,2126]